var title_f28_45_29392="Mobilizing vagina and rectum";
var content_f28_45_29392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a small rectovaginal fistula through a transvaginal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 445px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior vaginal wall is sharply mobilized off of the anterior rectal wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29392=[""].join("\n");
var outline_f28_45_29392=null;
var title_f28_45_29393="Plasma cell leukemia";
var content_f28_45_29393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasma cell leukemia (PCL)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peripheral blood smear of patients with plasma cell leukemia demonstrates a leukocytosis with circulating plasma cells. By definition, the absolute plasma cell count must exceed 2000/microL or 20 percent of the peripheral white blood cell count. The morphological features of plasma cells can differ depending upon their maturity. Mature plasma cells are oval with abundant basophilic cytoplasm. The nucleus is round and eccentrically located with a marked perinuclear hof, or cytoplasmic clearing. The nucleus contains \"clock-face\" or \"spoke wheel\" chromatin without nucleoli. Immature plasma cells have dispersed nuclear chromatin, prominent nucleoli and a high nuclear to cytoplasmic ratio.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anderson, SC, PhD. Anderson's Atlas of Hematology. Copyright 2003, Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29393=[""].join("\n");
var outline_f28_45_29393=null;
var title_f28_45_29394="Down syndrome";
var content_f28_45_29394=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Down syndrome (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/45/29394/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29394/contributors\" id=\"au6096\">",
"       Kathryn K Ostermaier, MD, FAAP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/45/29394/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29394/contributors\" id=\"se603\">",
"       Helen V Firth, DM, FRCP, DCH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/45/29394/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29394/contributors\" id=\"de2295\">",
"       Elizabeth TePas, MD, MS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29394/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/45/29394?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Down syndrome is the most common form of intellectual disability in the world. It occurs in about 1 out every 1,000 babies born alive, and it is caused by a genetic abnormality that affects something called a chromosome.",
"    </p>",
"    <p>",
"     Chromosomes are large structures found in cells that house thousands of genes. People without genetic abnormalities have 23 pairs of chromosomes, and each pair is given a number between 1 and 23.",
"    </p>",
"    <p>",
"     People with Down syndrome are born with three &mdash; rather than two &mdash; copies of chromosome 21. Scientists do not know why some babies wind up with the extra chromosome, but they do know that the age of the mother plays a role. As a woman gets older, her risk of having a baby with Down syndrome steadily increases. The father's age may also be relevant, but scientists do not yet know that definitively.",
"    </p>",
"    <p>",
"     This article will discuss what to expect if your baby has been diagnosed with Down syndrome. For information about how Down syndrome is diagnosed during pregnancy, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"      \"Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DIFFERENCES IN APPEARANCE",
"     </span>",
"    </p>",
"    <p>",
"     If your baby has Down syndrome, you may not be able to tell immediately after birth that anything is different about him or her. Even so, most babies with Down syndrome have at least some physical characteristics that distinguish them from babies with a normal chromosomal complement:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Newborns &mdash; Most newborns with Down syndrome will have at least a few of the following features:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       A flattened face (",
"       <a class=\"graphic graphic_picture graphicRef67446 \" href=\"UTD.htm?33/56/34690\">",
"        picture 1",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Extra skin at back of the neck",
"      </li>",
"      <li>",
"       Eyes that slant upwards",
"      </li>",
"      <li>",
"       A lack of muscle tone (hypotonia)",
"      </li>",
"      <li>",
"       Abnormally flexible joints",
"      </li>",
"      <li>",
"       Unusual looking ears",
"      </li>",
"      <li>",
"       A crease across the palm, called a transverse palmar crease (",
"       <a class=\"graphic graphic_picture graphicRef61017 \" href=\"UTD.htm?25/21/25951\">",
"        picture 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       A wide gap between the first and second toes (sandal gap deformity)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Children and adults &mdash; As they grow into adulthood, children with Down syndrome also develop many of the following characteristics (if they don't already have them) (",
"       <a class=\"graphic graphic_figure graphicRef79537 \" href=\"UTD.htm?20/55/21365\">",
"        figure 1",
"       </a>",
"       ):",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       A flattened head in back (brachycephaly)",
"      </li>",
"      <li>",
"       Skin folds on the eyelids",
"      </li>",
"      <li>",
"       A flattened nose bridge",
"      </li>",
"      <li>",
"       Folded, unusual, or small ears",
"      </li>",
"      <li>",
"       A gaping mouth",
"      </li>",
"      <li>",
"       A protruding tongue",
"      </li>",
"      <li>",
"       Abnormal teeth",
"      </li>",
"      <li>",
"       A short neck",
"      </li>",
"      <li>",
"       Short, broad hands",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DOWN SYNDROME COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Aside from its effects on appearance, Down syndrome can cause a number of medical complications. Some of these complications are more serious than others, but most of them can be treated. To make sure that your child's complications are appropriately managed as they emerge, have him or her screened at regular intervals (",
"     <a class=\"graphic graphic_table graphicRef50749 \" href=\"UTD.htm?42/25/43420\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Potentially serious complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most serious complications of Down syndrome include heart defects, blood disorders that can include leukemia (cancer of the blood), and immune system problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Heart defects",
"     </span>",
"     &nbsp;&mdash;&nbsp;About half of all babies with Down syndrome are born with (often repairable) heart defects. Usually these defects affect the walls separating the four chambers of the heart.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Blood disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Down syndrome can cause blood cell abnormalities, including a form of blood cancer called leukemia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Immune system problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;The immune system of people with Down syndrome may not work as it should. As a result, people with Down syndrome are more vulnerable than others to infections, certain kinds of cancer, and autoimmune conditions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Stomach and digestive system",
"     </span>",
"     &nbsp;&mdash;&nbsp;About 5 percent of babies with Down syndrome have abnormally formed digestive organs, which can block the GI tract and may require surgery. They are also more prone to celiac disease, a condition that impairs their ability to absorb nutrients and that makes them unable to tolerate a protein in wheat called gluten. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=see_link\">",
"      \"Patient information: Celiac disease in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Hormonal disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Down syndrome can affect the way the body produces or responds to hormones. For example, people with Down syndrome often do not make sufficient thyroid hormone, which can contribute to problems with weight. They are also at risk for type 1 diabetes, which requires treatment with insulin injections.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Skeletal problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with Down syndrome often have too much flexibility between the bones at the top of the spine that support the head (called atlantoaxial instability). Often this condition causes no symptoms, but it can compress the spine, cause pain, or cause the head to tilt to one side. In extreme cases, this joint instability can cause paralysis.",
"    </p>",
"    <p>",
"     Children who participate in sports or other activities, such as the Special Olympics, should have a physical examination to look for signs of joint instability.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Other complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Less serious complications include those affecting vision and hearing, and those that lead to other non-life-threatening conditions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Intellectual disability",
"     </span>",
"     &nbsp;&mdash;&nbsp;Almost all babies born with Down syndrome are intellectually disabled, but the degree of impairment can vary a lot. Despite the disability, most children with DS can learn basic tasks; they just take a little longer than other babies to do so. Table 2 lists the average ages at which babies with Down syndrome reach certain milestones (",
"     <a class=\"graphic graphic_table graphicRef71712 \" href=\"UTD.htm?4/12/4299\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Height and weight",
"     </span>",
"     &nbsp;&mdash;&nbsp;Babies with Down syndrome are usually smaller than other babies, and they have smaller heads. They may also grow more slowly, and may never reach the same heights that normal children do.",
"    </p>",
"    <p>",
"     Although children with Down syndrome grow less than usual, they tend to gain more weight possibly from a slower metabolism. As a result, parents need to guard against obesity by encouraging exercise and, if necessary, limiting the amount of food the child eats.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Vision",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most children with Down syndrome have some sort of vision problem, such as nearsightedness, farsightedness, or astigmatism (an abnormal curvature of the eye that causes blurred vision). They may also have weak eye muscles (cross-eyed) or have abnormal eye movements that impair vision. Glasses can often correct these problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Hearing loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nearly 80 percent of people with Down syndrome develop some degree of hearing impairment, sometimes requiring a hearing aid. Children with Down syndrome are also much more prone than other children to having ear infections. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"      \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Skin",
"     </span>",
"     &nbsp;&mdash;&nbsp;The majority of children with Down syndrome have a skin disorder of one sort or another. These disorders are not usually cause for concern. Examples include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Thickened skin on the palms and soles",
"      </li>",
"      <li>",
"       Flaky, scaling skin on the scalp and other oily parts of the body",
"      </li>",
"      <li>",
"       Pink marbling of the skin",
"      </li>",
"      <li>",
"       Dry skin",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Behavior",
"     </span>",
"     &nbsp;&mdash;&nbsp;Behavioral and psychological problems are more common among children with Down syndrome than among other children. Common disorders include attention deficit hyperactivity disorder, oppositional disorder, and aggressive disorders. As many as 7 percent of children with Down syndrome have an autism spectrum disorder. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=see_link\">",
"      \"Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"      \"Patient information: Autism spectrum disorders (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Sleep apnea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Up to 75 percent of children with Down syndrome have sleep apnea, a sleep disorder that causes them to intermittently stop breathing while asleep. The condition is often tied to being overweight, but among children with Down syndrome, it happens even when weight is not an issue. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link\">",
"      \"Management of obstructive sleep apnea in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Fertility",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with Down syndrome are usually fertile and may become pregnant. If you have a daughter, it's important to educate her about sex and how to take precautions against unwanted pregnancy. Nearly all men with Down syndrome are infertile. Still, if you have a son, it's important to educate him about appropriate behavior when it comes to sex.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      DOWN SYNDROME DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Down syndrome is usually diagnosed during pregnancy. If Down syndrome is not diagnosed during pregnancy, healthcare providers can usually diagnose Down syndrome based on the infant's appearance. In such cases, the diagnosis should be confirmed using a blood test that examines the child's chromosomes (karyotype).",
"    </p>",
"    <p>",
"     For a thorough discussion of prenatal Down syndrome diagnosis, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"      \"Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      DOWN SYNDROME TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There is no treatment specifically for Down syndrome, but there are several important treatments for the complications of the condition. That's why it's important to have your child screened for these complications at regular intervals throughout his or her youth (",
"     <a class=\"graphic graphic_table graphicRef50749 \" href=\"UTD.htm?42/25/43420\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Having your child routinely screened can help ensure that he or she will get the appropriate treatment as soon as any Down syndrome-related complications arise. That can be important for serious complications as well as for not so serious ones. For example, your child may need corrective surgery to treat a heart defect. Or your child may need eyeglasses or hearing aids &mdash; not only to improve vision or hearing, but also to maximize his or her ability to learn and understand.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      DOWN SYNDROME PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The prognosis for a child with Down syndrome used to be pretty grim. In 1983 the average lifespan of a person with the condition was just 25 years. Thanks to advances in the treatment and screening of people with Down syndrome, the landscape has changed. Just 14 years later, in 1997, the average lifespan had nearly doubled to 49 years.",
"    </p>",
"    <p>",
"     As medicine continues to evolve, the outlook for people with Down syndrome will probably keep improving. Even now, many children with the condition go on to have full and happy lives, so long as they have the right support.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H343100528\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263301109\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=see_link\">",
"      Patient information: Down syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/50/11043?source=see_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/31/31218?source=see_link\">",
"      Patient information: Newborn appearance (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H263301117\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=see_link\">",
"      Patient information: Celiac disease in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/8/33922?source=see_link\">",
"      Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13224?source=see_link\">",
"      Management of Down syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link\">",
"      Management of obstructive sleep apnea in children",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/downsyndrome.html\">",
"        www.nlm.nih.gov/medlineplus/downsyndrome.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       Association for Children with Down Syndrome (",
"       <a class=\"external\" href=\"file://www.acds.org/\">",
"        www.acds.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       March of Dimes Birth Defects Foundation (",
"       <a class=\"external\" href=\"file://www.marchofdimes.com/baby/birthdefects_downsyndrome.html\">",
"        www.marchofdimes.com/baby/birthdefects_downsyndrome.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Association for Down Syndrome (",
"       <a class=\"external\" href=\"file://www.nads.org/\">",
"        www.nads.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Down Syndrome Congress (",
"       <a class=\"external\" href=\"file://www.ndsccenter.org/\">",
"        www.ndsccenter.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Down Syndrome Society (",
"       <a class=\"external\" href=\"file://www.ndss.org/\">",
"        www.ndss.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Child Health and Human Development (",
"       <a class=\"external\" href=\"file://www.nichd.nih.gov/health/topics/down/pages/default.aspx\">",
"        www.nichd.nih.gov/health/topics/down/Pages/default.aspx",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/45/29394/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/45/29394?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29394/abstract/1\">",
"      Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics 2011; 128:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29394/abstract/2\">",
"      Roizen NJ, Patterson D. Down's syndrome. Lancet 2003; 361:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29394/abstract/3\">",
"      Toledo C, Alembik Y, Aguirre Jaime A, Stoll C. Growth curves of children with Down syndrome. Ann Genet 1999; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29394/abstract/4\">",
"      Weijerman ME, van Furth AM, Vonk Noordegraaf A, et al. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr 2008; 152:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_45_29394=[""].join("\n");
var outline_f28_45_29394=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DIFFERENCES IN APPEARANCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DOWN SYNDROME COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           DOWN SYNDROME DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           DOWN SYNDROME TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           DOWN SYNDROME PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21365\" title=\"figure 1\">",
"           DS features PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/56/34690\" title=\"picture 1\">",
"           Child Down syndrome PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/21/25951\" title=\"picture 2\">",
"           Palm crease PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?42/25/43420\" title=\"table 1\">",
"           Down syndrome monitoring PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?4/12/4299\" title=\"table 2\">",
"           Down syndrome milestones PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_45_29395="Diagram of pathologic changes with CAV";
var content_f28_45_29395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Diagram of pathologic changes with CAV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Differences between typical nontransplant coronary atherosclerosis and typical transplant vasculopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Finn Gustafsson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29395=[""].join("\n");
var outline_f28_45_29395=null;
var title_f28_45_29396="Construction of ileal conduit";
var content_f28_45_29396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Construction of an ileal conduit during pelvic exenteration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29396=[""].join("\n");
var outline_f28_45_29396=null;
var title_f28_45_29397="Cosyntropin (tetracosactide): Pediatric drug information";
var content_f28_45_29397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cosyntropin (tetracosactide): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"    see \"Cosyntropin (tetracosactide): Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cortrosyn&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cortrosyn&trade;;",
"     </li>",
"     <li>",
"      Synacthen&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diagnostic Agent, Adrenocortical Insufficiency",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Adrenocortical insufficiency, diagnostic test: Note:",
"     </b>",
"     Cosyntropin injection solution formulation is not recommended for I.M. administration; use powder for injection formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preterm neonates: Limited data available; reported range: I.M., I.V.: 0.1-3.5",
"     <b>",
"      mcg",
"     </b>",
"     /kg/dose. In 276 ELBW neonates, a dose of 1",
"     <b>",
"      mcg",
"     </b>",
"     /kg was found to be superior to 0.1",
"     <b>",
"      mcg",
"     </b>",
"     /kg in assessing adrenal function; in addition, the 0.1",
"     <b>",
"      mcg",
"     </b>",
"     /kg/dose given I.M. produced a significantly lower response than when given I.V. (mean GA: 25.5 weeks; mean birth weight: 743 g) (Watterberg, 2005). Physiologic doses of 0.1",
"     <b>",
"      mcg",
"     </b>",
"     /kg were used to test adrenal function in VLBW neonates [mean birth weight 900 g; mean GA: 27 weeks (range: 23-32 weeks)]; only 36% of neonates responded; increasing the dose to 0.2",
"     <b>",
"      mcg",
"     </b>",
"     /kg resulted in 67% of the neonates responding, but sensitivity of the test was decreased (Korte, 1996). Doses of 3.5",
"     <b>",
"      mcg",
"     </b>",
"     /kg were administered to test adrenal function in 44 preterm neonates (mean birth weight: 823 g; mean GA: 26.2 weeks; mean postmenstrual age: 30.1 weeks) during inhaled beclomethasone therapy (Cole, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Full-term neonates: I.M., I.V.: 15",
"     <b>",
"      mcg",
"     </b>",
"     /kg/dose",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"      see \"Cosyntropin (tetracosactide): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adrenocortical insufficiency, diagnostic test: Note:",
"     </b>",
"     Cosyntropin injection solution formulation is not recommended for I.M. administration; use powder for injection formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &le;2 years: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: 0.125 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: 15",
"     <b>",
"      mcg",
"     </b>",
"     /kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;2 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     I.M., I.V.: 0.25 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Doses in the range of 0.25-0.75 mg have been used in clinical studies; however, maximal response is seen with 0.25 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     I.V. infusion: 0.25 mg administered over 6 hours (rate: 0.04 mg/hour); may be useful when greater cortisol stimulation required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing (low-dose): Children &ge;5 years and Adolescents: I.V.: 1",
"     <b>",
"      mcg",
"     </b>",
"     (Cemeroglu, 2011; Kazlauskaite, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Congenital adrenal hyperplasia, evaluation:",
"     </b>",
"     Infants and Children: I.M., I.V.: 0.125-0.25 mg (Speiser, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Adrenocortical insufficiency, diagnostic test:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Cosyntropin injection solution formulation is not recommended for I.M. administration; use powder for injection formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conventional dose: I.M., I.V.: 0.25 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Doses in the range of 0.25-0.75 mg have been used in clinical studies; however, maximal response is seen with 0.25 mg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. infusion: 0.25 mg administered over 6 hours (rate: 0.04 mg/hour); may be useful when greater cortisol stimulation required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Low-dose protocol: I.M., I.V.: 1",
"     <b>",
"      mcg",
"     </b>",
"     (Abdu, 1999);",
"     <b>",
"      Note:",
"     </b>",
"     The use of the low-dose protocol has been advocated by some clinicians, particularly in mild or secondary adrenal insufficiency. The low-dose protocol is not recommended in critically ill patients (Marik, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 0.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortrosyn&trade;: 0.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 0.25 mg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: For powder for injection, reconstitute vial with 1 mL NS (concentration: 0.25 mg/mL); visually inspect solution for discoloration and particulate matter prior to injection. Contains no preservatives; discard unused portion of vial after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Powder for injection: Administer as 0.25 mg/mL concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection solution: Not recommended for I.M. administration per manufacturer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. push: For standard doses, administer dose in 2-5 mL of NS over 2 minutes. For low doses, cosyntropin 1",
"     <b>",
"      mcg",
"     </b>",
"     /mL (final volume: 1 mL) and 0.5",
"     <b>",
"      mcg",
"     </b>",
"     /mL (final volume: 2 mL) have been reported (Abdu, 1999; Cemeroglu, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. infusion: Dilute dose in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; infuse over 4-8 (~0.04 mg/hour over 6 hours)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for injection: Store intact vial at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution for injection: Store refrigerated between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light and freezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion: Stable for 12 hours at room temperature when diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; stable for 21 days under refrigeration; incompatible with plasma or blood infusions; inactivation by enzymes may occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency [FDA approved in pediatric patients (age not specified) and adults]; has also been used in the diagnosis of congenital adrenal hyperplasia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cortrosyn&reg; may be confused with colchicine, corticorelin, corticotropin, Cotazym&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cosyntropin may be confused with corticorelin, corticotropin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse events associated with other corticosteroids may be observed when Synacthen&reg; Depot (Canadian availability) is used for therapeutic purposes. Refer to corticosteroid monographs for comprehensive lists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypertension, peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Whealing with redness at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Synacthen&reg; Depot (Canadian availability): Adrenal hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cosyntropin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing allergic disease or a history of allergic reactions to corticotropin",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ClonazePAM: Cosyntropin may enhance the hepatotoxic effect of ClonazePAM.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Cosyntropin may enhance the hepatotoxic effect of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrazepam: Cosyntropin may enhance the hepatotoxic effect of Nitrazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Cosyntropin may enhance the hepatotoxic effect of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Cosyntropin may enhance the hepatotoxic effect of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Cosyntropin may enhance the hepatotoxic effect of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Cosyntropin may enhance the hepatotoxic effect of Valproic Acid.  Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1051968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma cortisol concentrations should be measured immediately before and exactly 30 minutes after the dose; dose should be given in the early morning; normal morning baseline cortisol &gt;5 mcg/dL (SI: &gt;138 nmol/L); normal response 30 minutes after cosyntropin injection: an increase in serum cortisol concentration of &ge;7 mcg/dL (SI: &ge;193 nmol/L) or peak response &gt;18 mcg/dL (SI: &gt;497 nmol/L). If increase in plasma cortisol levels at 30 minutes is equivocal, consider repeat cortisol sampling at 60 and/or 90 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M., I.V.: Within 5 minutes increases in plasma cortisol concentrations are observed in healthy individuals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: I.M., I.V.: 45-60 minutes peak plasma cortisol concentration",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each 0.25 mg of cosyntropin is equivalent to 25 units of corticotropin.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdu TA, Elhadd TA, Neary R, et al, \"Comparison of the Low Dose Short Synacthen Test (1 Microg), the Conventional Dose Short Synacthen Test (250 Microg), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients With Pituitary Disease,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1999, 84(3):838-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/10084558/pubmed\" id=\"10084558\" target=\"_blank\">",
"        10084558",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cemeroglu AP, Kleis L, Postellon DC, et al, \"Comparison of Low-Dose and High-Dose Cosyntropin Stimulation Testing in Children,\"",
"      <i>",
"       Pediatr Int",
"      </i>",
"      , 2011, 53(2):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/20626639/pubmed\" id=\"20626639\" target=\"_blank\">",
"        20626639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cole CH, Shah B, Abbasi S, et al, \"Adrenal Function in Premature Infants During Inhaled Beclomethasone Therapy,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1999, 135(1):65-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/10393606/pubmed\" id=\"10393606\" target=\"_blank\">",
"        10393606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kazlauskaite R, Evans AT, Villabona CV, et al, \"Corticotropin Tests for Hypothalamic-Pituitary-Adrenal Insufficiency: A Metaanalysis,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(11):4245-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/18697868/pubmed\" id=\"18697868\" target=\"_blank\">",
"        18697868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Korte C, Styne D, Merritt TA, et al, \"Adrenocortical Function in the Very Low Birth Weight Infant: Improved Testing Sensitivity and Association With Neonatal Outcome,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(2):257-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/8636825 /pubmed\" id=\"8636825 \" target=\"_blank\">",
"        8636825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marik PE, Pastores SM, Annane D, et al, \"Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(6):1937-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/18496365/pubmed\" id=\"18496365\" target=\"_blank\">",
"        18496365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Speiser PW, Azziz R, Baskin LS, et al, \"Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(9):4133-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/20823466/pubmed\" id=\"20823466\" target=\"_blank\">",
"        20823466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thaler LM and Blevins LS Jr, \"The Low Dose (1-Microg) Adrenocorticotropin Stimulation Test in the Evaluation of Patients With Suspected Central Adrenal Insufficiency,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1998, 83(8):2726-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/9709938/pubmed\" id=\"9709938\" target=\"_blank\">",
"        9709938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watterberg KL, Shaffer ML, Garland JS, et al, \"Effect of Dose on Response to Adrenocorticotropin in Extremely Low Birth Weight Infants,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2005, 90(12):6380-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29397/abstract-text/16159938/pubmed\" id=\"16159938\" target=\"_blank\">",
"        16159938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13183 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29397=[""].join("\n");
var outline_f28_45_29397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154800\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051966\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442271\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051960\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154785\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154772\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051970\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051963\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051969\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154837\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154836\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051974\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051959\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299097\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219534\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154782\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447516\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051968\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051958\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051972\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051975\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13183\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13183|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=related_link\">",
"      Cosyntropin (tetracosactide): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_45_29398="Tositumomab radioconjugate: Drug information";
var content_f28_45_29398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tositumomab radioconjugate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/36/7749?source=see_link\">",
"    see \"Tositumomab radioconjugate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bexxar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Non-Hodgkin&rsquo;s lymphoma (NHL), relapsed or refractory:",
"     </b>",
"     I.V.: Dosing consists of four components administered in 2 steps. Refer to manufacturer&rsquo;s labeling for additional details. Indicated for a single treatment course. Thyroid protective agents (SSKI, Lugol's solution or potassium iodide) should be administered beginning at least 24 hours prior to step 1 (Refer to Additional Information or Pharmacotherapy Pearls). Premedicate with acetaminophen 650 mg and diphenhydramine 50 mg orally 30 minutes prior to step 1 and step 2.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Step 1: Dosimetric step (Day 0):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tositumomab 450 mg administered over 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iodine I 131 tositumomab (containing I-131 5 mCi and tositumomab 35 mg) administered over 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Whole body dosimetry and biodistribution should be determined on Day 0; days 2, 3, or 4; and day 6 or 7 prior to administration of Step 2. If biodistribution is not acceptable, do not administer the therapeutic step. On day 6 or 7, calculate the patient specific activity of iodine I 131 tositumomab to deliver 75 cGy total body dose (TBD) or 65 cGy TBD (in mCi).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Step 2: Therapeutic step (one dose administered 7-14 days after step 1):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tositumomab 450 mg administered over 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Iodine I 131 tositumomab:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelets &ge;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Iodine I 131 calculated to deliver 75 cGy total body irradiation and tositumomab 35 mg over 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and &lt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Iodine I 131 calculated to deliver 65 cGy total body irradiation and tositumomab 35 mg over 20 minutes",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F7998505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion-related toxicity (with tositumomab or iodine I-131 tositumomab):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate: Reduce infusion rate by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe: Interrupt infusion; after complete resolution, resume with previous infusion rate reduced by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Serious allergic reaction: Discontinue infusion.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Not all components are shipped from the same facility. When ordering, ensure that all will arrive on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kit [dosimetric package]: Tositumomab 225 mg/16.1 mL [2 vials], tositumomab 35 mg/2.5 mL [1 vial], and iodine I 131 tositumomab 0.1 mg/mL and 0.61mCi/mL (20 mL) [1 vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Kit [therapeutic package]: Tositumomab 225 mg/16.1 mL [2 vials], tositumomab 35 mg/2.5 mL [1 vial], and iodine I 131 tositumomab 1.1 mg/mL and 5.6 mCi/mL (20 mL) [1 or 2 vials]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F229513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:  Refer to manufacturer&rsquo;s labeling for additional details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab: Infuse over 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodine I 131 tositumomab: Infuse over 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Administer via an I.V. tubing set with an in-line 0.22 micron filter; do not change primary infusion set or filter at any time during the dosimetric or therapeutic step; changing the filter may result in up to a 7% loss of the iodine I 131 tositumomab dose (use the same infusion set and filter for tositumomab and iodine I 131 tositumomab). Flush with NS after Iodine I 131 tositumomab infusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prior to infusion, patients should be premedicated (with acetaminophen and an antihistamine) and a thyroid-protective agent should be started. Reduce the rate of tositumomab or iodine 131 tositumomab infusion by 50% for mild-to-moderate infusion-related toxicities; interrupt for severe infusion reaction (once severe infusion reaction has resolved, infusion may be restarted at half the previous rate). Discontinue for serious allergic reaction.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory CD20 positive, low-grade, follicular, or transformed non-Hodgkin's lymphoma (NHL), with progression during or after rituximab treatment",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F229542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (37%), pain (19%), chills (18%), headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (17%; grades 3/4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism (7% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (36%), abdominal pain (15%), vomiting (15%), anorexia (14%), diarrhea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Myelosuppression (grades 3/4: 71%; nadir: 4-7 weeks; duration: ~30 days), neutropenia (grades 3/4: 63%; median duration: 31 days; grade 4: 25%), thrombocytopenia (grades 3/4: 53%; median duration: 32 days; grade 4: 21%), lymphocytopenia (recovery: ~12 weeks after treatment), anemia (grades 3/4: 29%; median duration: 23 days; grade 4: 5%), secondary leukemia/myelodysplastic syndrome (overall: 3% to 10%; 2-year follow-up: 2% to 5%; 5-year follow-up: 6% to 15%), hemorrhage (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (46%), myalgia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (21%), pharyngitis (12%), dyspnea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infusion-related reactions (29%, occurred within 14 days of infusion, included bronchospasm, chills, dyspnea, fever, hypotension, nausea, rigors, diaphoresis); infection (21% to 45%, serious: 9%);g HAMA-positive seroconversion (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (7%), peripheral edema (9%), chest pain (7%), vasodilation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (5%), somnolence (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (6%), dyspepsia (6%), weight loss (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site hypersensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (10%), back pain (8%), neck pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (10%), pneumonia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (8%), hypersensitivity/allergic reaction (6%), secondary malignancies (nonhematologic: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic reaction, angioedema, bacteremia, bronchitis, dehydration, flu-like syndrome, herpes virus infection, laryngismus, pleural effusion, septicemia, serum sickness, skin infections",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F229516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F229500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radioactive isotopes:",
"     <b>",
"      [U.S. Boxed Warning]: Treatment involves radioactive isotopes and should only be administered by or under supervision of physicians enrolled in the Bexxar&reg; therapeutic regimen certification program; appropriate precautions for handling and administration must be followed.",
"     </b>",
"     Patients must be instructed in measures to minimize exposure of others.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiopharmacuetical: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and prolonged cytopenias, including neutropenia and thrombocytopenia are common; do not administer in patients with &gt;25% lymphoma marrow involvement, platelet count &lt;100,000/mm",
"      <sup>",
"       3",
"      </sup>",
"      or neutrophil count &lt;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      .",
"     </b>",
"     Hematologic toxicity is reported to be the most common adverse effect with 27% patients requiring supportive care; cytopenias may be prolonged and severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious hypersensitivity reactions (including anaphylaxis) have been reported; permanently discontinue for severe reaction; medications for the treatment of reactions should be readily available in the event of severe reactions.",
"     </b>",
"     Signs and symptoms of severe allergic reactions include fever, rigors/chills, sweating, hypotension, dyspnea, bronchospasm, or nausea; may occur during or within 48 hours of infusion. Premedicate with acetaminophen and diphenhydramine prior to both the dosimetric and therapeutic doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothyroidism: Treatment may lead to hypothyroidism; patients should receive thyroid-blocking medications beginning at least 24 hours prior to the dosimetric dose and continued for 2 weeks after the therapeutic dose. The median time to development of hypothyroidism was 16 months (range: up to 90 months). Evaluate TSH and for signs and symptoms of hypothyroidism at baseline and annually thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:  Patients should be premedicated to prevent infusion-related reactions; interrupt infusion and/or decrease infusion rate for infusion-related reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Myelodysplastic syndrome (MDS) and acute leukemia have been reported; median time to development was 31 months. Nonhematologic malignancies, including skin cancer and solid tumors, have also been reported following use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety has not been established in patients with renal impairment. Excretion is primarily renal; impaired renal function may increase exposure; clearance of radiolabeled iodine is decreased in patients with renal impairment or genitourinary obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The duration of severe hematologic toxicity may be prolonged in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women of childbearing potential: Women of childbearing potential should be advised of potential fetal risk; effective contraceptive measures should be used during and for 12 months following treatment (males and females).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: The safety and efficacy of live vaccines in patients who have received therapy with tositumomab have not been established. Avoid administration of live vaccines in patients recently treated with tositumomab.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F229504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F229519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodine-131 crosses the placenta and may cause severe and irreversible hypothyroidism in neonates; women of childbearing potential should be advised of potential fetal risk. The risk of miscarriage may also be increased for up to 1 year after treatment. Pregnancy should be ruled out prior to therapy. Males and females of childbearing potential should be instructed to use effective contraception during and for 12 months following treatment. Fertility may be affected for up to 12 months following therapy. Infants born to treated mothers should be monitored for hypothyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F229536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F229520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Radioiodine and immunoglobulins are excreted in breast milk. Quantity of radioiodine may be greater than maternal serum concentrations. Women should be advised to discontinue nursing prior to therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Bexxar Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 mg/mL (34.7 mL): $3414.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Bexxar 131 Iodine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.61 mci/mL (20 mL): $3615.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5.6 mci/mL (20 mL): $34873.19",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F229509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and weekly for up to 12 weeks, or longer for persistent severe cytopenia); signs and symptoms of hypothyroidism and TSH (prior to therapy and yearly); renal function; signs/symptoms of infusion or allergic reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Following infusion of the iodine I 131 tositumomab dosimetric dose, the total body gamma camera counts and whole body images should be taken within 1 hour of the infusion and prior to urination, and 2-4 days after the infusion and following urination, and 6-7 days after the infusion and following urination.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F229499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tositumomab is a murine IgG",
"     <sub>",
"      2a",
"     </sub>",
"     lambda monoclonal antibody which binds to the CD20 antigen, expressed on B-lymphocytes and on &gt;90% of B-cell non-Hodgkin's lymphomas. Iodine I 131 tositumomab is a radio-iodinated derivative of tositumomab covalently linked to iodine 131. The possible actions of the regimen include apoptosis, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and radiation-induced cell death. Administration results in depletion of CD20 positive cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F229515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset: CD20-positive cell depletion: &le;7 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: CD20-positive cell recovery begins at ~12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Tositumomab: V",
"     <sub>",
"      d",
"     </sub>",
"     increased with high tumor burden, splenomegaly, or bone marrow involvement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Tositumomab: 67 hours (range: 28-115 hours); decreased with high tumor burden, splenomegaly, or bone marrow involvement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Iodine-131 elimination occurs by decay and urinary excretion; after 5 days total body clearance is 67% of a dose (98% in urine)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29398/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaminski MS, Radford JA, Gregory S, et al, &ldquo;Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin&rsquo;s Lymphoma Who Had Previously Responded to I-131 Tositumomab,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(31):7985-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29398/abstract-text/16204016/pubmed\" id=\"16204016\" target=\"_blank\">",
"        16204016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaminski MS, Tuck M, Estes J, et al, &ldquo;131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(5):441-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29398/abstract-text/15689582/pubmed\" id=\"15689582\" target=\"_blank\">",
"        15689582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaminski MS, Zelenetz AD, Press OW, et al, &ldquo;Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(19):3918-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29398/abstract-text/11579112/pubmed\" id=\"11579112\" target=\"_blank\">",
"        11579112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Link BK, Martin P, Kaminski MS, et al, &ldquo;Cyclophosphamide, Vincristine, and Prednisone Followed by Tositumomab and Iodine-131-Tositumomab in Patients With Untreated Low-Grade Follicular Lymphoma: Eight-Year Follow-Up of a Multicenter Phase II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(18):3035-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29398/abstract-text/20458031/pubmed\" id=\"20458031\" target=\"_blank\">",
"        20458031",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Press OW, Eary JF, Appelbaum FR, et al, &ldquo;Phase II Trial of 131I-B1 (Anti-CD20) Antibody Therapy With Autologous Stem Cell Transplantation for Relapsed B Cell Lymphomas,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 346(8971):336-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Press OW, Unger JM, Braziel RM, et al, &ldquo;Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-up of Southwest Oncology Group Protocol S9911,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(25):4143-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/45/29398/abstract-text/16896003/pubmed\" id=\"16896003\" target=\"_blank\">",
"        16896003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Press OW, Unger JM, LeBlanc ML, et al, &ldquo;A Phase III Randomized Intergroup Trial (S0016) Comparing CHOP Plus Rituximab With CHOP Plus Iodine-131-Tositumomab for Front-Line Treatment of Follicular Lymphoma: Results of Subset Analyses and a Comparison of Prognostic Models,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(15s):8001 [abstract 8001 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10160 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29398=[""].join("\n");
var outline_f28_45_29398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708914\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229529\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229544\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229532\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062236\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998505\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229498\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229513\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402326\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229542\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229516\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229500\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300157\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229504\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229519\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229536\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229520\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324005\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229509\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229499\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229515\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10160|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/36/7749?source=related_link\">",
"      Tositumomab radioconjugate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_45_29399="Pelvic packing";
var content_f28_45_29399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic packing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 606px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Pelvic packing is performed through a 6-8 cm midline incision made from the pubic symphysis cephalad and the midline fascia is divided.",
"    <br>",
"     (B) The pelvic hematoma often dissects the preperitoneal and paravesical space toward the presacral region, thereby facilitating packing. If this has not occuured, blunt digital dissection is performed to open the preperitoneal space.",
"     <br>",
"      (C) Three standard surgical laparotomy pads are placed on each side of the bladder deep within the preperitoneal space. If a suprapubic tube is placed, it should exit through a separate stab incision, cephalad to the incision either in the midline or slightly off midline. The midline fascia is closed with a running suture and the skin is reapproximated with staples.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29399=[""].join("\n");
var outline_f28_45_29399=null;
var title_f28_45_29400="Chronic complications of the short bowel syndrome in children";
var content_f28_45_29400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic complications of the short bowel syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Jon A Vanderhoof, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Rosemary J Pauley-Hunter, NP-C, MS, RN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Craig Jensen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29400/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/45/29400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short bowel syndrome is a malabsorptive state that may follow massive resection of the small intestine. Short bowel syndrome in children usually results from necrotizing enterocolitis and congenital intestinal anomalies. Complications of short bowel syndrome are related to the site of resection, the process of ileal adaptation, and the need for parenteral nutrition over the short or long-term. Acute complications that can occur anytime include watery diarrhea, electrolyte disturbances, and catheter-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. More chronic complications include liver and biliary disease associated with parenteral nutrition, bacterial overgrowth-induced arthritis, colitis, and D-lactic acidosis, nutritional deficiencies, and enteric hyperoxaluria. Patients with intractable complications may be candidates for small bowel transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronic complications of short bowel syndrome in children are reviewed here. An overview of the management of short bowel syndrome and its pathogenesis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link\">",
"     \"Management of the short bowel syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link\">",
"     \"Pathophysiology of the short bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic is also discussed in a position statement and technical review, issued by the American Gastroenterological Association (AGA). The",
"    <a class=\"external\" href=\"file://www.gastrojournal.org/article/S0016-5085(03)00052-0/fulltext\">",
"     AGA position statement for short bowel syndrome and intestinal transplantation",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/4\">",
"     4",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WATERY DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Watery diarrhea is the most common early complication of short bowel syndrome in children. It may occur any time, but particularly when enteral nutrition is advanced. Most often, it occurs when the osmotic fluid load in the small intestine exceeds the absorptive capacity.",
"   </p>",
"   <p>",
"    Fluid losses and electrolyte imbalance are common in patients who have undergone massive intestinal resection. Frequent monitoring of serum and stool electrolytes is critical to providing adequate replacement fluids. Situations that may exacerbate hypovolemia (eg, excessive heat exposure) should be avoided.",
"   </p>",
"   <p>",
"    Management of watery diarrhea may include dietary changes, the use of somatostatin analogs,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , or antisecretory agents, as described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Switching from bolus to continuous enteral feedings [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/5\">",
"       5",
"      </a>",
"      ], switching to a low carbohydrate, high fat enteral formula, slowing the enteral infusion rate, or diluting enteral formulas may be beneficial in diminishing output.",
"     </li>",
"     <li>",
"      Treatment with acid-suppressing medications can be helpful during the first few months after resection because gastric hypersecretion is common during the postoperative period and may lead to increased fluid production and losses. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Esophagitis/Peptic ulcer disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      , which binds the malabsorbed bile acids that are increased in the colon following ileal resection may help diminish the effects of secretory diarrhea related to bile acid malabsorption. However, cholestyramine must be used judiciously since some patients may have bile acid deficiency; in these patients, cholestyramine may bind the few remaining bile salts that are necessary for fat absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/6\">",
"       6",
"      </a>",
"      ]. Improvement in the diarrhea during a trial of cholestyramine supports the diagnosis of choleretic diarrhea. In this case, the medication should be continued, but the patient should be monitored for nutritional status (weight gain) and for fat soluble vitamin deficiencies.",
"     </li>",
"     <li>",
"      Anti-secretory agents, including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"       loperamide",
"      </a>",
"      , have demonstrated safety in children and may be efficacious in slowing gut transit when taken an hour before meals.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       Clonidine",
"      </a>",
"      , an alpha-2 adrenergic receptor agonist, has been reported to decrease high intestinal fluid output in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/7,8\">",
"       7,8",
"      </a>",
"      ], but it has not been studied in children.",
"     </li>",
"     <li>",
"      Use of somatostatin analogs, while beneficial short term, has not resulted in long term benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CATHETER RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications related to the indwelling catheter occur in most patients who require long term parenteral nutrition because of short bowel syndrome, and include catheter related infection and catheter breakage and occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter-related blood stream infections can be life-threatening in infants and children. Moreover, episodes of central catheter infection are associated with hyperbilirubinemia and progressive liver disease. Cholestasis develops in many infants after the initial catheter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link&amp;anchor=H4#H4\">",
"     \"Parenteral nutrition-associated liver disease in infants\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most infections occur in the first month after hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/15\">",
"     15",
"    </a>",
"    ], and special attention must be paid to ensure that the caregivers are well instructed in central line care. Sterile technique, particularly in the initiation and discontinuation of parenteral therapy, is critical to the prevention of line contamination. Bacterial translocation from unhealthy gut epithelium also can be a factor in recurrent line infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. Ethanol Lock therapy has decreased catheter related infectious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/17\">",
"     17",
"    </a>",
"    ] although its use may be associated with the development of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/18\">",
"     18",
"    </a>",
"    ]; nonetheless, a trial should be attempted in infants with recurrent central line infections. Catheter exit site infections can usually be treated with sterile dressing changes and antibiotics if treatment is initiated early in the course.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of bloodstream infections is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28632?source=see_link\">",
"     \"Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninfective complications of central venous catheters can be prevented by standardized protocols for insertion and long term care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/19\">",
"     19",
"    </a>",
"    ]. Vigorous flushing protocols are key to the maintenance of line patency. Various clot dissolving agents can be used to restore line patency if occlusion occurs. This procedure is usually performed by nurses in the emergency department or nurses from nutrition support teams. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\", section on 'Thrombolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proper instruction on the care of the catheter must be provided, including the avoidance of over-clamping and limiting the use of scissors near the line. Repair kits are available for most catheters. The use of these kits by knowledgeable caregivers can extend the life of the central line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HEPATOBILIARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with short bowel syndrome who require long-term parenteral nutrition are at risk for the development of liver disease and cholelithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral nutrition associated liver disease (PNALD), also known as parenteral nutrition-associated cholestasis, is seen in 40 to 60 percent of children who receive long-term parenteral nutrition. Severe and progressive liver disease is most common in infants and neonates. The liver disease is progressive as long as oral alimentation is withheld, and can lead to cirrhosis, portal hypertension, and liver failure, and is a major indication for combined liver-small bowel transplantation. With careful management, which includes maximizing enteral nutrition, many children will be able to be weaned from parenteral nutrition before their native liver becomes irreversibly damaged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link\">",
"     \"Management of the short bowel syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of PNALD, including the possible role of the lipid emulsion in its pathogenesis and management, is presented in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"     \"Parenteral nutrition-associated liver disease in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these efforts, some patients progress to liver failure and require liver transplantation. If the infant or child is close to the point where parenteral nutrition can begin to be discontinued, isolated liver transplantation may be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/20\">",
"     20",
"    </a>",
"    ]. If not, then a combined liver-small bowel transplant may be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of the short bowel syndrome in children\", section on 'Small bowel transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with short bowel syndrome experience an increased incidence of gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. One study of 84 adult patients with severe short bowel syndrome found asymptomatic gallstones in 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/23\">",
"     23",
"    </a>",
"    ]. In another report, gallstones were found in 4 of 24 children who had ileal resection in the newborn period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of cholelithiasis in patients with the short bowel syndrome is not completely understood. At least two factors may contribute:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interruption of the enterohepatic circulation of bile acids by ileal resection results in a reduction in hepatic bile acid secretion and an altered composition of hepatic bile, which becomes supersaturated with respect to cholesterol.",
"     </li>",
"     <li>",
"      Diminished enteric hormonal stimulation of meal-induced gallbladder contraction may lead to biliary stasis and the formation of biliary sludge, a precursor of gallstone formation. While the use of continuous enteral nutrition initially facilitates bowel adaptation, induction of gall bladder contraction requires larger, meal-induced stimulation of CCK release.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for the development of gallstones in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ileal resection",
"     </li>",
"     <li>",
"      Absence of an ileocecal valve",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      (especially in low birth weight infants) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/6/37991?source=see_link\">",
"       Octreotide",
"      </a>",
"      use (risk better established in adults) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A greater number of abdominal operations",
"     </li>",
"     <li>",
"      Longer duration of parenteral nutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures to prevent the development of gallstones in patients who are dependent upon parenteral nutrition have been proposed, but none has been widely adopted. Oral administration of ursodeoxycholic acid is sometimes used to improve bile flow and reduce gall bladder stasis, although there is little data to suggest that prophylactic use prevents gallstones or parenteral nutrition associated liver disease. Prophylactic cholecystectomy has also been suggested as a means of preventing gallstones patients with short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ESOPHAGITIS/PEPTIC ULCER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric hypersecretion commonly occurs after small bowel resection in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/29\">",
"     29",
"    </a>",
"    ]. Gastric hypersecretion may lead to esophagitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peptic ulcer disease, leading to diminished appetite. In addition, gastric hypersecretion is associated with increased fluid production and losses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/30\">",
"     30",
"    </a>",
"    ], and the increased acidity may inactivate pancreatic enzymes, resulting in decreased nutrient absorption.",
"   </p>",
"   <p>",
"    For these reasons, the use of acid-suppressing medications is often recommended for individuals with short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/4,31\">",
"     4,31",
"    </a>",
"    ]. Acid-suppressing medications are often given in the early stages after resection, and these should be continued if the medication appears to reduce fluid losses. Acid suppressing medications also may be necessary when symptoms of esophagitis or gastritis develop. However, long-term use of proton pump inhibitors should be limited if possible because of potential side effects, including effects on bone metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of gastroesophageal reflux disease in children and adolescents\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANASTOMOTIC ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcers at the site of previous intestinal resection can cause occult or frank bleeding. Endoscopic examination may be necessary to identify the source of bleeding. Treatment includes use of anti-inflammatory medications, such as oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21173?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and, less commonly, resection of the anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BACTERIAL OVERGROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial overgrowth, defined as increased numbers and species of bacteria in the small intestine creating inflammation, is especially problematic in patients with short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/11\">",
"     11",
"    </a>",
"    ]. Bacterial growth in the normal bowel is controlled by gastric acid, pancreatic enzyme activity, enterocyte turnover, normal antegrade peristaltic activity in the small intestine, and the ileocecal valve. Compromise of one or both of the last two mechanisms is common in the short bowel syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients have no ileocecal valve, the primary means for preventing reflux of bacteria from the colon into the small intestine",
"     </li>",
"     <li>",
"      Progressive dilatation of the small intestine as part of the adaptation response limits the efficacy of peristalsis in ridding the small intestine of bacteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The excess bacteria may exacerbate malabsorption by several mechanisms. Bacterial deconjugation of bile acids diminishes the intestinal absorption of monoglycerides and fatty acids. In addition, the inflammatory response caused by bacterial overgrowth damages the absorptive surface, resulting in malabsorption and protein loss.",
"   </p>",
"   <p>",
"    Clinical manifestations of bacterial overgrowth include an increase in energy requirement and weight loss. In more severe cases, colitis and ileitis may occur, which can resemble Crohn disease, although a more diffuse inflammatory picture may be more common [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, the enteritis can elicit an inflammatory cascade with resultant inflammatory arthritis. Mild to moderate enteritis associated with short bowel bacterial overgrowth delays weaning of parenteral nutrition and, therefore, requires attention. Finally, bacterial overgrowth is associated with more frequent blood stream infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Catheter related complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical manifestations and pathogenesis of bacterial overgrowth are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of bacterial overgrowth is made most commonly by breath testing. Antibiotic treatment is effective but, in many cases, requires repeated or cyclical dosing. Administration of anti-inflammatory drugs, such as corticosteroids and salicylate products may be necessary in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/33\">",
"     33",
"    </a>",
"    ]. Children with short bowel syndrome often withhold their stools, which may exacerbate conditions of overgrowth. Cisapride has been suggested as a potentially useful therapy in patients with pediatric short-bowel syndrome with gastrointestinal dysmotility, but this drug must be used with caution because it increases the risk for cardiac arrhythmias (QT prolongation) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/34\">",
"     34",
"    </a>",
"    ]. When the bacterial overgrowth is related to small bowel dilation, intestinal tapering procedures may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=see_link&amp;anchor=H841534#H841534\">",
"     \"Management of the short bowel syndrome in children\", section on 'Bowel tailoring and lengthening procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     D-lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-Lactic acidosis is another metabolic complication of short bowel syndrome most commonly seen in patients with an intact colon and bacterial overgrowth. The delivery of unabsorbed carbohydrate to the colon causes gram-positive anaerobic bacteria to produce D-lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. By contrast, the lactate produced by normal metabolic processes is L-lactate. Patients with short bowel syndrome frequently demonstrate chronically elevated serum concentrations of D-lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. They usually are asymptomatic, but carbohydrate loading can produce severe metabolic acidosis and a characteristic and recurrent neurologic syndrome consisting of confusion, cerebellar ataxia, and slurred speech. The clinical manifestations, diagnosis, and treatment of D-lactic acidosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=see_link\">",
"     \"D-Lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NUTRIENT DEFICIENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with short bowel syndrome are at greatest risk for nutrient deficiencies while parenteral nutrition support is being tapered and after it is discontinued. In one series of children aged two to nine years undergoing transition from parenteral to enteral nutrition, 33 percent had at least one vitamin deficiency and 77 percent had a mineral deficiency prior to the transition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/40\">",
"     40",
"    </a>",
"    ]. The frequencies of these deficiencies were higher after transition to full enteral nutrition; the most common deficiencies were of vitamin D, zinc, and iron. Because the amount of micronutrient absorption is uncertain after transition to enteral nutrition, patients should be monitored carefully for nutrient deficiencies. Most protocols suggest measuring vitamin and mineral levels when parenteral nutrition is first discontinued to establish baseline values, and then serially until supplement needs are established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malabsorption of fat soluble vitamins, particularly A, D, and E, are common.",
"     </li>",
"     <li>",
"      Trace element deficiencies, especially iron, zinc, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       selenium",
"      </a>",
"      also occur because of increased fecal losses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/42\">",
"       42",
"      </a>",
"      ]. Decreased serum zinc concentration in association with decreased serum alkaline phosphatase suggests zinc deficiency severe enough to cause poor growth and impaired intestinal adaptation. Oral supplementation should be initiated as indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link\">",
"       \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"       \"Iron requirements and iron deficiency in adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link\">",
"       \"Zinc deficiency and supplementation in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin B12 (cobalamin) deficiency is common is patients who have undergone ileal resection. Vitamin B12 deficiency results in macrocytic anemia and has been associated with the development of osteoporosis in adult males [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/43\">",
"       43",
"      </a>",
"      ]. Vitamin B12 replacement therapy requires either intra-nasal or parenteral administration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"       \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Magnesium deficiency also is common. It is manifest by symptoms of fatigue, depression, muscle weakness, and excitability. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=see_link\">",
"       \"Signs and symptoms of magnesium depletion\"",
"      </a>",
"      .) Magnesium deficiency is difficult to treat since oral magnesium is poorly absorbed and causes in osmotic diarrhea; some patients may require parenteral supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced bone mineral content may occur due to altered acid-base status, specific nutrient deficiencies (eg, magnesium, calcium, Vitamin D) and protein energy malabsorption. Serum phosphorous and calcium should be monitored every three months (with the other nutrients) during the first year after parenteral nutrition has been discontinued. Calcium and phosphorous supplementation should be initiated as indicated. The dose is individualized depending upon the child's age, weight, mineral deficit, and ongoing losses. Baseline and annual evaluation of bone density with dual energy X-ray absorptiometry (DEXA) is recommended for all children with short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/44\">",
"     44",
"    </a>",
"    ]. Research in this area is ongoing, and a study in adults demonstrated that human growth hormone increased markers of bone turnover and stabilized femoral bone neck mass [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HYPEROXALURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperoxaluria is another potential problem in patients with short bowel syndrome, as it is for patients with any form of fat malabsorption (except for those who do not have a colon in continuity with intestinal contents). Hyperoxaluria predisposes to formation of kidney stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link\">",
"     \"Epidemiology of and risk factors for nephrolithiasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in oxalate absorption and subsequent excretion in this setting is related to two factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The binding of free calcium to fatty acids in the intestinal lumen",
"     </li>",
"     <li>",
"      The increased colonic permeability to small molecules, such as oxalate, which is induced by exposure to nonabsorbed bile salts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with malabsorption may have factors other than increased oxalate excretion predisposing to stone formation. The diarrheal fluid losses can lead both to a reduction in urine volume and, if the patient has a metabolic acidosis, a low urine pH and a marked decrease in citrate excretion; these changes can promote uric acid, as well as calcium oxalate stone formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk factors for calcium stones in adults\", section on 'Hyperoxaluria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of enteric hyperoxaluria is directed toward diminishing intestinal oxalate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/46\">",
"     46",
"    </a>",
"    ]. The initial regimen consists of a low oxalate diet, a high fluid intake, and potassium citrate to correct metabolic acidosis if present. A study in children demonstrated that hypocitruria was a primary risk factor in stone formation, not hypercalciuria, as previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, close regulation of metabolic balance is needed. Other therapies, which have not been studied in controlled trials, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low-fat, low-oxalate diet (",
"      <a class=\"graphic graphic_table graphicRef68231 \" href=\"UTD.htm?40/43/41661\">",
"       table 1",
"      </a>",
"      ) may be helpful in reducing the quantity of fatty acids and free oxalate in the colon. This diet, however, often is nutritionally inadequate in patients who have short bowel syndrome.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      , which binds both bile acids and oxalate, also can be used, but side effects may be limiting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a case report, conjugated bile acid replacement therapy was reported to reduce fecal fat excretion and urinary oxalate excretion, and improve nutritional status in a patient with short bowel syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29400/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Watery diarrhea and electrolyte disturbances are the most common early complications of short bowel syndrome in children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Watery diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who require long-term parenteral nutrition are at risk of catheter-related sepsis, as well as catheter breakage and occlusion. Proper instruction on the care of the catheter must be provided. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Catheter related complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who require long-term parenteral nutrition are also at risk for development of liver disease and cholelithiasis. The most important step in preventing or retarding the development of liver disease is to maximize enteral feeding. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hepatobiliary disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link\">",
"       \"Parenteral nutrition-associated liver disease in infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastric hypersecretion commonly occurs after small bowel resection in infants and children. Patients with signs or symptoms of peptic disease or with excessive fluid losses in the early phases after bowel resection should be treated with acid suppressing medications. These medications should not be used long term without reassessment of the benefits and potential risks. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Esophagitis/Peptic ulcer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anastomotic ulcers at the site of previous intestinal resection can cause occult or frank bleeding. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Anastomotic ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial overgrowth, defined as increased numbers and unusual species of bacteria creating inflammation in the small intestine, may be problematic in patients with short bowel syndrome, if inflammation occurs. Clinical manifestations include an increase in energy requirement and weight loss. In more severe cases, colitis and ileitis may occur, which can resemble Crohn's disease, although a more diffuse inflammatory picture may be more common. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bacterial overgrowth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with short bowel syndrome are at greatest risk for nutrient deficiencies during and after the time that parenteral nutrition is being discontinued. Vitamin and mineral levels should be measured at the time of discontinuation, then periodically as needed based on the need for supplementation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nutrient deficiencies'",
"      </a>",
"      above.) Baseline and annual evaluation of bone density with dual energy X-ray absorptiometry (DEXA) is valuable in assessment of bone health and prevention of complications. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Osteoporosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteric hyperoxaluria is another potential problem in patients with any form of fat malabsorption (except for those who do not have a colon in continuity with intestinal contents). Such patients are at increased risk for kidney stones. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hyperoxaluria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/1\">",
"      Duro D, Kamin D, Duggan C. Overview of pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr 2008; 47 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/2\">",
"      Ekema G, Milianti S, Boroni G. Total parenteral nutrition in patients with short bowel syndrome. Minerva Pediatr 2009; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/3\">",
"      Nucci AM, Barksdale EM Jr, Beserock N, et al. Long-term nutritional outcome after pediatric intestinal transplantation. J Pediatr Surg 2002; 37:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/4\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: short bowel syndrome and intestinal transplantation. Gastroenterology 2003; 124:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/5\">",
"      Joly F, Dray X, Corcos O, et al. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009; 136:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/6\">",
"      Allard JP, Jeejeebhoy KN. Nutritional support and therapy in the short bowel syndrome. Gastroenterol Clin North Am 1989; 18:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/7\">",
"      McDoniel K, Taylor B, Huey W, et al. Use of clonidine to decrease intestinal fluid losses in patients with high-output short-bowel syndrome. JPEN J Parenter Enteral Nutr 2004; 28:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/8\">",
"      Buchman AL, Fryer J, Wallin A, et al. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr 2006; 30:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/9\">",
"      Lamrani A, Vidon N, Sogni P, et al. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997; 43:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/10\">",
"      Sadlier C. Intestinal failure and long-term parenteral nutrition in children. Paediatr Nurs 2008; 20:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/11\">",
"      Cole CR, Frem JC, Schmotzer B, et al. The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses. J Pediatr 2010; 156:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/12\">",
"      Cole CR, Hansen NI, Higgins RD, et al. Bloodstream infections in very low birth weight infants with intestinal failure. J Pediatr 2012; 160:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/13\">",
"      Sondheimer JM, Asturias E, Cadnapaphornchai M. Infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr 1998; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/14\">",
"      Beath SV, Davies P, Papadopoulou A, et al. Parenteral nutrition-related cholestasis in postsurgical neonates: multivariate analysis of risk factors. J Pediatr Surg 1996; 31:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/15\">",
"      Mohammed A, Grant FK, Zhao VM, et al. Characterization of posthospital bloodstream infections in children requiring home parenteral nutrition. JPEN J Parenter Enteral Nutr 2011; 35:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/16\">",
"      Terra RM, Plopper C, Waitzberg DL, et al. Remaining small bowel length: association with catheter sepsis in patients receiving home total parenteral nutrition: evidence of bacterial translocation. World J Surg 2000; 24:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/17\">",
"      Wales PW, Kosar C, Carricato M, et al. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience. J Pediatr Surg 2011; 46:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/18\">",
"      Wong T, Clifford V, McCallum Z, et al. Central venous catheter thrombosis associated with 70% ethanol locks in pediatric intestinal failure patients on home parenteral nutrition: a case series. JPEN J Parenter Enteral Nutr 2012; 36:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/19\">",
"      Pittiruti M, Hamilton H, Biffi R, et al. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). Clin Nutr 2009; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/20\">",
"      Horslen SP, Sudan DL, Iyer KR, et al. Isolated liver transplantation in infants with end-stage liver disease associated with short bowel syndrome. Ann Surg 2002; 235:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/21\">",
"      Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology 1997; 113:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/22\">",
"      Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/23\">",
"      Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992; 33:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/24\">",
"      Teitelbaum DH, Han-Markey T, Drongowski RA, et al. Use of cholecystokinin to prevent the development of parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 1997; 21:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/25\">",
"      Randall LH, Shaddy RE, Sturtevant JE, et al. Cholelithiasis in infants receiving furosemide: a prospective study of the incidence and one-year follow-up. J Perinatol 1992; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/26\">",
"      Radetti G, Gentili L, Paganini C, Messner H. Cholelithiasis in a newborn following treatment with the somatostatin analogue octreotide. Eur J Pediatr 2000; 159:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/27\">",
"      Yetkin DO, Boysan SN, Tiryakioglu O, et al. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocr J 2007; 54:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/28\">",
"      Thompson JS. The role of prophylactic cholecystectomy in the short-bowel syndrome. Arch Surg 1996; 131:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/29\">",
"      Hyman PE, Everett SL, Harada T. Gastric acid hypersecretion in short bowel syndrome in infants: association with extent of resection and enteral feeding. J Pediatr Gastroenterol Nutr 1986; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/30\">",
"      Jeppesen PB, Staun M, Tjellesen L, Mortensen PB. Effect of intravenous ranitidine and omeprazole on intestinal absorption of water, sodium, and macronutrients in patients with intestinal resection. Gut 1998; 43:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/31\">",
"      Kaufman SS, Loseke CA, Lupo JV, et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr 1997; 131:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/32\">",
"      Taylor SF, Sondheimer JM, Sokol RJ, et al. Noninfectious colitis associated with short gut syndrome in infants. J Pediatr 1991; 119:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/33\">",
"      Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/34\">",
"      Raphael BP, Nurko S, Jiang H, et al. Cisapride improves enteral tolerance in pediatric short-bowel syndrome with dysmotility. J Pediatr Gastroenterol Nutr 2011; 52:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/35\">",
"      Andres AM, Thompson J, Grant W, et al. Repeat surgical bowel lengthening with the STEP procedure. Transplantation 2008; 85:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/36\">",
"      Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int 1996; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/37\">",
"      Bongaerts G, Bakkeren J, Severijnen R, et al. Lactobacilli and acidosis in children with short small bowel. J Pediatr Gastroenterol Nutr 2000; 30:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/38\">",
"      Bongaerts G, Tolboom J, Naber T, et al. D-lactic acidemia and aciduria in pediatric and adult patients with short bowel syndrome. Clin Chem 1995; 41:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/39\">",
"      Goulet O, Colomb-Jung V, Joly F. Role of the colon in short bowel syndrome and intestinal transplantation. J Pediatr Gastroenterol Nutr 2009; 48 Suppl 2:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/40\">",
"      Yang CF, Duro D, Zurakowski D, et al. High prevalence of multiple micronutrient deficiencies in children with intestinal failure: a longitudinal study. J Pediatr 2011; 159:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/41\">",
"      Van Gossum A, Cabre E, H&eacute;buterne X, et al. ESPEN Guidelines on Parenteral Nutrition: gastroenterology. Clin Nutr 2009; 28:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/42\">",
"      Matarese LE, Steiger E. Dietary and medical management of short bowel syndrome in adult patients. J Clin Gastroenterol 2006; 40 Suppl 2:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/43\">",
"      Tucker KL, Hannan MT, Qiao N, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005; 20:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/44\">",
"      Dellert SF, Farrell MK, Specker BL, Heubi JE. Bone mineral content in children with short bowel syndrome after discontinuation of parental nutrition. J Pediatr 1998; 132:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/45\">",
"      Tangpricha V, Luo M, Fern&aacute;ndez-Est&iacute;variz C, et al. Growth hormone favorably affects bone turnover and bone mineral density in patients with short bowel syndrome undergoing intestinal rehabilitation. JPEN J Parenter Enteral Nutr 2006; 30:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/46\">",
"      Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/47\">",
"      Obialo CI, Clayman RV, Matts JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int 1991; 39:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/48\">",
"      Tekin A, Tekgul S, Atsu N, et al. A study of the etiology of idiopathic calcium urolithiasis in children: hypocitruria is the most important risk factor. J Urol 2000; 164:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29400/abstract/49\">",
"      Emmett M, Guirl MJ, Santa Ana CA, et al. Conjugated bile acid replacement therapy reduces urinary oxalate excretion in short bowel syndrome. Am J Kidney Dis 2003; 41:230.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5886 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29400=[""].join("\n");
var outline_f28_45_29400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WATERY DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CATHETER RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HEPATOBILIARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gallstones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ESOPHAGITIS/PEPTIC ULCER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANASTOMOTIC ULCERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BACTERIAL OVERGROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      D-lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NUTRIENT DEFICIENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HYPEROXALURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5886\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5886|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/43/41661\" title=\"table 1\">",
"      Oxalate content food AGA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=related_link\">",
"      D-Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28632?source=related_link\">",
"      Epidemiology of and risk factors for Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=related_link\">",
"      Epidemiology of and risk factors for nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/33/19994?source=related_link\">",
"      Management of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26778?source=related_link\">",
"      Management of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=related_link\">",
"      Pathophysiology of the short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_45_29401="Nephrology pattern 4";
var content_f28_45_29401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 4",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut G Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29401=[""].join("\n");
var outline_f28_45_29401=null;
var title_f28_45_29402="Management of cardiac risk for noncardiac surgery";
var content_f28_45_29402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of cardiac risk for noncardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Jonathan B Shammash, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Stephen E Kimmel, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29402/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/45/29402/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/45/29402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INITIAL RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac complications pose one of the most significant risks to patients undergoing major noncardiac surgery. The risk of perioperative cardiac complications in an individual patient can be initially assessed by the presence or absence of clinical predictors of increased perioperative cardiovascular risk, the patient's level of cardiac functional status, and the underlying risk of the surgical procedure. This approach is discussed in detail separately but will be briefly summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of risk indices are available to estimate the perioperative risk. These risk indices were derived from patients who were candidates for surgery; they did not include patients with high-risk conditions that were considered major predictors of risk in the 2007 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines that require intensive management and often lead to delay in or cancellation of surgery (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"UTD.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer the revised Goldman cardiac risk index (RCRI), which is the best validated, is simple to use, and appears to have greater predictive value than at least some of the other models (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The type of surgery also must be taken into account (",
"    <a class=\"graphic graphic_table graphicRef57828 \" href=\"UTD.htm?7/2/7212\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H21#H21\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Revised cardiac risk index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of algorithms have been proposed for the assessment of patients prior to noncardiac surgery, including those from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/1\">",
"     1",
"    </a>",
"    ], the American College of Physicians (",
"    <a class=\"graphic graphic_algorithm graphicRef73341 graphicRef60714 \" href=\"UTD.htm?40/4/41027\">",
"     algorithm 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], the European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/European",
"    </span>",
"    Society of Anaesthesiology",
"    <span class=\"nowrap\">",
"     (ESC/ESA)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef60723 \" href=\"UTD.htm?33/4/33860\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/7\">",
"     7",
"    </a>",
"    ], and Fleisher and Eagle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These approaches all have the following general features that apply only to patients in different risk categories undergoing nonemergent surgery (",
"    <a class=\"graphic graphic_table graphicRef62292 \" href=\"UTD.htm?26/56/27532\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at low risk generally require no further evaluation before surgery.",
"     </li>",
"     <li>",
"      Patients at high risk (eg, those with signs or symptoms of severe or unstable coronary disease) often undergo coronary arteriography to see if any correctable lesions are present (",
"      <a class=\"graphic graphic_table graphicRef70833 \" href=\"UTD.htm?37/47/38652\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients at intermediate risk represent a heterogeneous group that includes those at low and high risk. The use of noninvasive testing can be used to identify the risk category of an individual patient. Noninvasive testing has a negative predictive value of almost 100 percent for perioperative death or nonfatal MI but a positive predictive value of less than 20 percent (eg, 98 and 18 percent, respectively in a review of five studies of dipyridamole-thallium imaging) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4,9\">",
"       4,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We prefer either the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    algorithm or the Fleisher-Eagle algorithm to determine the need for additional cardiac testing prior to major noncardiac surgery because the predictors used largely overlap with the revised Goldman cardiac risk index [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic approach to patients considered at high risk will be reviewed here. The major issues are the indications for and method of revascularization and medical therapies, such as beta blockers and statins.",
"   </p>",
"   <p>",
"    The perioperative evaluation and management of heart failure in relation to noncardiac surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=see_link\">",
"     \"Perioperative heart failure in noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although obese patients are at increased risk of a cardiovascular complication at the time of surgery, the evaluation and management is slightly different than in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H16#H16\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Obese patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REVASCULARIZATION VERSUS MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with stable coronary artery disease, the indications for revascularization include those with left main or severe three vessel disease or those with angina refractory to medical therapy and lesser degrees of obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H23#H23\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with stable coronary artery disease without indications for revascularization who are scheduled to undergo noncardiac surgery, the evidence presented below suggests that most such patients do not benefit from prophylactic revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/6,8,10\">",
"     6,8,10",
"    </a>",
"    ]. However, each study has significant limitations and they differ from each other in significant ways.",
"   </p>",
"   <p>",
"    We agree with the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (not changed in the 2009 focused update) and the 2009",
"    <span class=\"nowrap\">",
"     ESC/ESA",
"    </span>",
"    guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery, which recommend coronary revascularization for symptomatic patients with (1) high-risk unstable angina or non-ST-elevation MI, (2) acute ST-elevation MI, (3) angina and left main or three-vessel disease, or (4) angina and two-vessel disease if this includes proximal LAD stenosis as well as LV dysfunction or ischemia on stress testing, who require noncardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. It should be noted that the guidelines relied heavily on the CARP and DECREASE-V studies discussed below.",
"   </p>",
"   <p>",
"    When the guidelines are followed, the proportion of noncardiac surgery patients who undergo preoperative revascularization is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4\">",
"     4",
"    </a>",
"    ]. In three studies that used the approach in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, 2 to 11 percent of patients underwent coronary angiography and only 0 to 2 percent underwent preoperative revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The rate of intervention may be even lower in asymptomatic patients, since these studies included symptomatic patients who may have been more likely to undergo revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In those patients in whom a decision is made to recommend preoperative revascularization, it should be kept in mind that any reduction in risk will be at least in part counterbalanced by the risks associated with the revascularization procedure and, as described below, with the possible need to discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy in patients who have undergone coronary artery stenting. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Preoperative PCI'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CARP trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Coronary Artery Revascularization Prophylaxis (CARP) trial was a randomized comparison of preoperative revascularization (with either PCI or CABG) and medical therapy in patients with stable coronary disease undergoing major vascular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/14\">",
"     14",
"    </a>",
"    ]. Of 5859 patients scheduled for vascular operations, 1190 were considered to be at increased cardiac risk (based upon clinical factors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stress testing) and had no other exclusions to participation (urgent vascular surgery or severe coexisting illness). These patients underwent coronary angiography; an additional 680 patients were excluded because of left main coronary disease, severe left ventricular dysfunction (LVEF &le;20 percent), severe aortic stenosis, or coronary anatomy not suitable for revascularization.",
"   </p>",
"   <p>",
"    The remaining 510 patients (representing only 9 percent of the original study candidates) were randomly assigned to preoperative revascularization or medical management. Forty-nine percent of patients had a revised cardiac risk index &ge;2 and 13 percent had a score &ge;3 (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 2",
"    </a>",
"    ). Two-thirds of the study subjects had either one- or two-vessel disease. Of those assigned to revascularization, 41 percent underwent CABG and 59 percent underwent PCI (based upon clinician preference). Subsequent vascular surgery was performed for either abdominal aortic aneurysm (33 percent) or lower extremity arterial disease (67 percent).",
"   </p>",
"   <p>",
"    The trial was designed to have sufficient power to examine long-term mortality, but not to provide a definitive analysis of perioperative events. The following outcomes were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative MI by cardiac enzymes occurred with comparable frequency in patients assigned to revascularization and those assigned to medical therapy (11.6 versus 14.3 percent).",
"     </li>",
"     <li>",
"      There were no differences between the revascularization and medical arms in left ventricular ejection fraction at three months (54 versus 55 percent).",
"     </li>",
"     <li>",
"      At a median of 2.7 years, the primary end point (all-cause mortality) was not significantly different in the revascularization and medical therapy groups (22 versus 23 percent, relative risk 0.98, 95% CI 0.70-1.37).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CARP trial was not designed to evaluate the best approach to screening or to decide who should undergo angiography. The study was also not large enough to provide a conclusive analysis of the potential benefit of revascularization in high-risk subgroups, such as those with a large stress-induced defect on radionuclide myocardial perfusion imaging or those with three vessel disease plus left ventricular dysfunction. However, a post-hoc, subset analysis did not show any significant lowering in the risk of death and nonfatal MI from preoperative revascularization in any risk groups, including the highest risk subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     DECREASE-V pilot study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate question is whether revascularization is of value in patients at somewhat higher risk than in CARP. This issue was addressed in 101 patients who had &ge;3 risk factors and had extensive stress-induced ischemia on noninvasive testing in the DECREASE-V Pilot Study, which showed no benefit from preoperative coronary revascularization at 30 days, one year, or during a median follow-up of 2.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, the study was underpowered and the revascularization group had more diabetes, angina, and prior strokes than the medical therapy group. Further study is needed in higher risk subgroups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Systematic versus selective screening angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the evidence discussed above does not suggest benefit from prophylactic revascularization, it is possible that benefit from such an approach in subsets of patients is possible. An attempt to address this issue was made in a trial which compared two approaches in 208 patients with Revised Cardiac Risk Index &ge;2 scheduled to undergo surgery for aorto-iliac obstructive disease or abdominal aortic aneurysm repair [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients were randomly assigned to screening with either systematic coronary angiography (n=105) or selective coronary angiography (n=103) based on the results of a positive noninvasive stress imaging test. Of the 103 patients in the selective screening group, 47 underwent angiography. Coronary revascularization was performed preoperatively in 58 and 40 percent of the two groups respectively if one or more major coronary vessel that showed a stenosis of &ge;70 percent (&ge;50 percent for the left main trunk).",
"   </p>",
"   <p>",
"    The primary end point was a combination (MACE) of non-fatal myocardial infarction, cerebrovascular accident, heart failure, the need for additional cardiac revascularization and death. The four year freedom MACE was significantly higher in the group that received systematic screening (87 versus 70 percent). Despite the limitations of this study, including its small size, lack of an independent events adjudication committee, unproven assumption that revascularization is better than medical therapy in patients without usual indications, and narrow indication for surgery (only patients with aorto-iliac disease), this study raises the possibility that for a narrow segment of patients undergoing noncardiac surgery, prophylactic coronary revascularization may improve outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     REVASCULARIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revascularization can be performed by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) using angioplasty alone or with stenting. The choice between CABG and PCI is affected by unique factors different from those when revascularization is considered in patients with stable angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H948409998\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, angiography is only warranted in a small number of asymptomatic patients undergoing noncardiac surgery (2 to 11 percent in series following the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     ESC/ESA",
"    </span>",
"    algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef60723 \" href=\"UTD.htm?33/4/33860\">",
"     algorithm 2",
"    </a>",
"    ) that included some symptomatic patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4,11-13\">",
"     4,11-13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Revascularization versus medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This decision is usually based upon the results of noninvasive testing. The main indications for noninvasive testing in asymptomatic patients are estimated high risk (&ge;3 revised cardiac index criteria) or intermediate risk (1 to 2 revised cardiac index criteria) plus poor or indeterminate functional status, a history consistent with coronary disease, or high-risk surgery (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70833 \" href=\"UTD.htm?37/47/38652\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/1,5-8,18\">",
"     1,5-8,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H43#H43\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Stress testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiography should be performed in patients with high-risk features on noninvasive testing (eg, reversible large anterior wall defect, multiple reversible defects, ischemia occurring at a low heart rate, extensive stress-induced wall motion abnormalities, transient ischemic dilatation). Angiography should also be performed in patients with high-risk unstable angina or myocardial infarction and these patients revascularized before surgery.",
"   </p>",
"   <p>",
"    The findings cited above in the CARP trial and DECREASE-V Pilot Study suggest that revascularization prior to noncardiac surgery should only be performed in patients who have high-risk coronary anatomy that fulfill current criteria applicable to all patients with coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. There does not appear to be any rationale for revising the threshold for revascularization because of the subsequent planned operation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elective surgery should be postponed in patients found to have significant lesions on coronary angiography until after myocardial revascularization with PCI or CABG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It seems reasonable to perform CABG in patients with established indications for CABG, such as significant left main disease or three vessel disease with impaired left ventricular function. In the absence of established indications, the benefit of CABG in reducing mortality associated with high-risk noncardiac surgery is unknown. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bypass surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      PCI should be performed in patients with lesions amenable to this procedure, and in patients in whom surgery cannot be postponed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity and mortality associated with sequential or combined CABG and noncardiac surgery is often in the same range as the perioperative morbidity and mortality that CABG is intended to reduce. The Coronary Artery Surgery Study (CASS) registry collected data on a large number of patients with coronary disease who underwent noncardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients treated with CABG prior to noncardiac surgery had a low risk for cardiac events during noncardiac surgery: 0.9 versus 2.4 percent in patients treated without revascularization. However, this benefit was offset by the 1.4 percent mortality associated with the CABG procedure itself.",
"   </p>",
"   <p>",
"    In contrast to these findings, other reports from the CASS registry suggest that surgical revascularization may provide a net reduction in perioperative and, in particular, long-term morbidity and mortality in selected patients with coronary disease who undergo major noncardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/20-23\">",
"     20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective cohort analysis evaluated 1834 patients with both coronary and peripheral artery disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/20\">",
"       20",
"      </a>",
"      ]. A significant long-term survival benefit was seen in patients who underwent CABG compared with medical therapy, regardless of the need for vascular surgery. Subgroup analysis suggested that the survival benefits with CABG were limited to patients with three-vessel disease, and were inversely related to the left ventricular ejection fraction.",
"     </li>",
"     <li>",
"      Another report evaluated the outcome of 3368 patients who underwent either high-risk (abdominal, vascular, thoracic, and head and neck) or low-risk (urologic, orthopedic, breast, and skin) noncardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/21\">",
"       21",
"      </a>",
"      ]. Among those undergoing high-risk surgery, the incidence of postoperative death and myocardial infarction (MI) were significantly lower in the patients in whom CABG was performed prior to noncardiac surgery (1.7 versus 3.3 percent and 0.8 versus 2.7 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar observations were noted in the subset of patients undergoing vascular surgery alone: CABG reduced the risk of MI compared to medical therapy (0.6 versus 8.5 percent), but did not significantly reduce the low rate of mortality (1.1 versus 2.8). By comparison, patients undergoing low-risk operations had a risk of postoperative death (&le;1 percent) or MI that was unaffected by prior CABG.",
"   </p>",
"   <p>",
"    Based upon these observations, it seems reasonable to perform elective CABG prior to high-risk noncardiac surgery in patients with established indications for CABG, such as significant left main disease or three vessel disease with impaired left ventricular function. In the absence of established indications, the benefit of CABG in reducing mortality associated with high-risk noncardiac surgery is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preoperative PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous coronary intervention, when indicated, can be performed before surgery with angioplasty alone or with stenting. These two approaches appear to impart different risks to major noncardiac surgery. Unlike the data showing improved outcomes with CABG prior to noncardiac surgery in some cases as discussed above, similar evidence is not available for preoperative revascularization with PCI. The discussion of the approach to patients in whom a decision is made for PCI prior to noncardiac surgery is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6344?source=see_link&amp;anchor=H350963316#H350963316\">",
"     \"Elective noncardiac surgery after percutaneous coronary intervention\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Patients who cannot undergo revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;If patients are deemed to be at risk but are not candidates for revascularization, alternatives include canceling or modifying surgery or proceeding to surgery with intensive intraoperative monitoring after the medical antiischemic regimen has been maximized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ROLE OF BETA BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers have an established role in protecting against perioperative cardiovascular events in patients undergoing coronary artery bypass graft surgery, the majority of whom are already on a beta blocker for other reasons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=see_link&amp;anchor=H7#H7\">",
"     \"Medical therapy to prevent complications after coronary artery bypass graft surgery\", section on 'Antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers have been commonly used in patients undergoing noncardiac surgery, particularly in those at high risk, to prevent cardiovascular events. However, studies evaluating their efficacy and safety in this setting have produced inconsistent results and have shown that beta blockers may cause harm.",
"   </p>",
"   <p>",
"    Support for the use of beta blockers prior to noncardiac surgery arose from initial randomized trials which suggested that beta blockers reduce perioperative ischemia in patients with underlying arterial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Possible mechanisms for such a benefit include a reduction in myocardial oxygen demand, as postoperative stress and high catecholamine levels can lead to adverse cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/27\">",
"     27",
"    </a>",
"    ], an increase in myocardial oxygen delivery due to prolongation of coronary diastolic filling time, prevention of fatal ventricular arrhythmias, and protection against plaque rupture in the setting of increased sympathetic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent randomized trials measuring hard end points have confirmed a reduction in myocardial infarction, but raised the possibility that beta blockers increase the risk of perioperative death and stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     POISE trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest trial, POISE, randomly assigned 8351 patients with or at risk of atherosclerotic disease (most with a revised cardiac risk index of 1 or 2), (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 2",
"    </a>",
"    ) undergoing noncardiac surgery (42 percent vascular surgery) to either fixed dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (100 mg controlled release metoprolol succinate) or placebo given two to four hours before surgery and repeated zero to six hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"     29",
"    </a>",
"    ]. This was followed by 200 mg of metoprolol or placebo daily for 30 days. Study drug administration was given if the heart rate was &ge;50 beats per minute and the systolic blood pressure was &ge;100 mmHg.",
"   </p>",
"   <p>",
"    The following findings were noted at 30 days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary end point of cardiovascular death, nonfatal myocardial infarction, or nonfatal cardiac arrest occurred significantly less often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      group (5.8 versus 6.9 percent, HR 0.84, 95% CI 0.70-0.99). This benefit was driven entirely by a reduction in MI (4.2 versus 5.7 percent).",
"     </li>",
"     <li>",
"      Total mortality and stroke were significantly increased in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      group (3.1 versus 2.3 percent and 1.0 versus 0.5 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant hypotension occurred significantly more often in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    group (15.0 versus 9.7 percent). A post hoc analysis suggested that hypotension accounted for no more than one-half of the strokes, but accounting for such a possible effect would entirely limit the increase in stroke risk. The higher frequency of hypotension in the metoprolol group raises the possibility that either the schedule or dose of beta blocker was not optimal. We believe that the POISE trial emphasizes the importance of avoiding hypotension if beta blockers are used.",
"   </p>",
"   <p>",
"    In an attempt to put the finding of an increased stroke risk into perspective, the POISE investigators performed a meta-analysis of six trials including POISE, which measured nonfatal stroke as an end point. The use of perioperative beta blockade was associated with a significantly increased risk of nonfatal stroke (HR 2.19, 95% CI 1.26-3.78). While POISE accounted for almost 80 percent of the patients in the meta-analysis, the relative risk of nonfatal stroke in the five trials before POISE was also higher, but did not achieve statistical significance (HR 2.98, 95% CI 0.74-12.0).",
"   </p>",
"   <p>",
"    Two other meta-analyses performed by the POISE investigators confirmed the findings in POISE, but POISE again accounted for approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk of death (RR 1.29; 95% CI 1.02-1.62) (seven trials; an eighth trial that was stopped early was excluded)",
"     </li>",
"     <li>",
"      A decreased risk of MI (RR 0.73; 95% CI 0.60-0.88) (six trials)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential major limitations of the POISE trial includes a very high and fixed dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (ie, no adjustment for heart rate) and initiation of therapy shortly before surgery (two to four hours compared to initiation as early as 30 days before surgery in some trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, we believe that POISE casts significant doubt on the benefit of prophylactic beta blockade and any net benefit is likely to reside in a smaller percentage of high-risk patients than was previously believed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much smaller randomized trials had conflicting results and significant flaws. The range of findings can be illustrated by the results of five of these trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 200 patients with or at risk for coronary heart disease undergoing noncardiac surgery, overall mortality at one year after hospital discharge was significantly lower for patients treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      given in the preanesthesia holding area and with oral or intravenous atenolol for up to 7 days postoperatively (3 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/32\">",
"       32",
"      </a>",
"      ]. However, differences in the atenolol and placebo populations with respect to preoperative cardiac risk factors and both preoperative and postoperative cardiac medication (including beta blockers and angiotensin converting enzyme inhibitors) administration limit confidence in these findings [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4,33\">",
"       4,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The DECREASE trial evaluated perioperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      therapy started at least one week before surgery in 112 high-risk patients undergoing major vascular surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/34\">",
"       34",
"      </a>",
"      ]. Compared with standard care, bisoprolol significantly reduced the incidence of cardiac mortality or MI at 30 days (3.4 versus 34 percent, relative risk 0.09, 95% CI 0.02-0.37) and two years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/35\">",
"       35",
"      </a>",
"      ]. Limitations of this trial included early stopping of the trial at a time when the number of events was very small [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/36\">",
"       36",
"      </a>",
"      ], lack of any blinding, and the extraordinary 90 percent reduction in 30-day events (2 versus 18) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4,30\">",
"       4,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The DECREASE-IV trial (which was unblinded and terminated early due to slow enrollment) randomly assigned over 1000 intermediate-risk patients scheduled to undergo noncardiovascular surgery in a 2 X 2 factorial design to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      (2.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo, AND to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      or placebo, starting at a median of 34 days before the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/37\">",
"       37",
"      </a>",
"      ]. The primary end point of the rate of myocardial infarction and cardiac death at 30 days occurred significantly less often in patients randomly assigned to bisoprolol (2.1 versus 6.0 percent). Four strokes occurred in the treatment group and three in the placebo group.",
"     </li>",
"     <li>",
"      The DiPoM trial found no benefit from perioperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      in 921 patients with type 2 diabetes who were to undergo surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/38\">",
"       38",
"      </a>",
"      ]. Limitations in the design of this trial included lack of titration of beta blockade to a target heart rate, short duration of therapy, the surgery was low risk in 39 percent of patients, and a number of protocol violations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4,38\">",
"       4,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lack of benefit was also noted in the MaVS trial in which 497 patients undergoing vascular surgery were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      or placebo starting two hours before surgery and continuing for only five days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/39\">",
"       39",
"      </a>",
"      ]. There was no significant difference in the 30-day cardiac event rate (10.2 versus 12.0 percent with placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence suggesting that beta blockers are of benefit only in the highest risk patients was provided by a retrospective study of 663,665 adults who underwent major noncardiac surgery in 2000 and 2001 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/40\">",
"     40",
"    </a>",
"    ]. Orthopedic and abdominal surgery accounted for 70 percent of cases. Perioperative beta blockers (within the first two days after admission) were given to 18 percent of patients overall, with the rate ranging from 14 percent with an RCRI score of 0 to 44 percent with a score &ge;4 (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H21#H21\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Revised cardiac risk index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute risk of in-hospital mortality according to the RCRI in patients who did not receive perioperative beta blockers increased progressively from 1.4 percent at a score of 0, to 7.4 percent at a score &ge;4. The patients with RCRI scores &ge;3 had clinically significant reductions in mortality with beta blocker therapy, but represented only 2 percent of patients. The 10 percent of patients with a RCRI of 2 had a small benefit, while the patients with an RCRI of 0 or 1 had no benefit and possible harm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 meta-analysis of 33 randomized trials evaluated outcomes in over 12,000 patients, of whom over 8000 were from POISE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/41\">",
"     41",
"    </a>",
"    ]. Beta blocker therapy was not associated with a significant reduction in the risk of either all-cause or cardiovascular mortality (odds ratios [OR] 1.20, 95% CI 0.95-1.51 and 1.15, 95% CI 0.85-1.16 respectively). A significant decrease in the rate of MI and a significant increase in the rate of stroke were also observed with beta blocker use (OR 0.65, 95% CI 0.54-0.79 and 2.16, 95% CI 1.27-3.68 respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Efficacy and safety summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the results of POISE and the subsequent meta-analysis, we believe that the evidence does not support the initiation of prophylactic perioperative beta blocker therapy in most patients undergoing noncardiac surgery (RCRI &le;2), (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 2",
"    </a>",
"    ). While beta blockers appear to decrease the risk of perioperative MI, the observed increases in the rate of stroke, and possibly in the rate total mortality, more than nullified this benefit in POISE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"     29",
"    </a>",
"    ]. A majority of the myocardial infarctions will be asymptomatic, but a few will result in serious complications in the perioperative period. In contrast, most of the strokes will be seriously disabling or incapacitating.",
"   </p>",
"   <p>",
"    POISE does not exclude benefit in high-risk patients (RCRI &ge;3), but such patients comprised only 2 percent of the population in the large observational study of 663,665 patients cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/40\">",
"     40",
"    </a>",
"    ]. Similarly, POISE does not exclude benefit of beta blockers in patients with evidence of significant ischemia by stress tests who do not undergo preoperative coronary revascularization. However, these patients may meet criteria for the initiation of beta blockers for other reasons.",
"   </p>",
"   <p>",
"    As most of the patients enrolled in the above studies were scheduled for vascular surgery, the issue of whether a high-risk cardiac patient undergoing intermediate-risk surgery has not been well studied. The potential benefits and risks of the initiation of preoperative beta blockers in this setting should be discussed in detail with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     If beta blockers are used",
"    </span>",
"    &nbsp;&mdash;&nbsp;If beta blockers are used, a number of issues must be addressed, including the choice of agent, dose and timing of therapy, and possible adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;All studies that have reported a cardiovascular benefit of perioperative beta blockers have used agents that are moderately (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) or highly (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ) beta-1 cardioselective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/42\">",
"     42",
"    </a>",
"    ]. There are no comparative prospective trials of the different beta-1 cardioselective agents. In those cases in which a decision is made to initiate a beta-1 cardioselective agent, limited comparative data are available that could be used to select a specific agent. Two large retrospective observational studies found a significant reduction in the relative risk of death at 30 days with atenolol, compared to metoprolol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonselective agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    are more likely to have adverse pulmonary and peripheral arterial effects. However, patients who are taking a nonselective beta blocker chronically do not need to switch to a beta-1 selective agent perioperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences in the half-lives of beta blockers exist and some experts feel that longer acting agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    are safer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Dose and resting heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conflicting evidence of benefit in the randomized trials cited above could reflect differences in dose, timing of administration, and potentially the attainment of target resting heart rates.",
"   </p>",
"   <p>",
"    In an observational study of 273 patients undergoing elective major vascular surgery, higher doses of beta blockers were associated with lower resting heart rates and lower heart rates were associated with significantly lower rates of troponin T release and myocardial ischemia and a reduced incidence of mortality and nonfatal myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/46\">",
"     46",
"    </a>",
"    ]. This conflicts with POISE, which used the largest dose of beta blockers and got the worst death outcomes. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'POISE trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with heart rates higher than 60 to 70",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    may be at increased risk of death or MI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 review by Auerbach and Goldman recommended that beta blockers should be started",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    titrated to a target heart rate of 60 to 65",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    before anesthesia is begun [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients in whom preoperative beta blocker therapy is chosen, the optimal timing of initiation is not clear. The following non-randomized observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefit was demonstrated when therapy was begun one month before surgery in DECREASE [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapy started a few hours before surgery was effective in one trial [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/32\">",
"       32",
"      </a>",
"      ], but not effective in POISE [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"       29",
"      </a>",
"      ] or MaVS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 940 patients scheduled to undergo vascular surgery, patients were divided into those who had beta blocker therapy initiated 0 to 1, &gt;1 to 4, and &gt;4 weeks before surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/48\">",
"       48",
"      </a>",
"      ]. Treatment initiation &gt;1 to 4 or &gt;4 weeks before surgery was associated with a lower heart rate and a significant (approximately 50 percent) reduction in the odds ratio for the composite endpoint of myocardial infarction and cardiac mortality at 30 days and long term compared to initiation at &lt;1 week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest starting beta blockers at least one and preferably four weeks before surgery. We speculate that this strategy will lessen the chance that they will cause or contribute to hypotension in the perioperative period.",
"   </p>",
"   <p>",
"    In patients who do not require long-term beta blocker therapy, the drug must be tapered carefully after surgery to avoid the potential adverse effects of rapid cessation such as accelerated angina, MI, or cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=see_link&amp;anchor=H5#H5\">",
"     \"Major side effects of beta blockers\", section on 'Beta blocker withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia, severe enough to require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    , has been reported in over 20 percent of patients receiving perioperative beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/25,32\">",
"     25,32",
"    </a>",
"    ], and significant hypotension occurred in 15 percent of treated patients in the POISE trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"     29",
"    </a>",
"    ]. Beta-1 cardioselective agents appear to be relatively well tolerated in patients with severe chronic obstructive pulmonary disease or reactive airways disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/4,50,51\">",
"     4,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Suggestions for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients in whom beta blockers are used perioperatively, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the risks of sudden cessation of beta blockers, therapy should be continued in patients who are already taking a beta blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/28,52\">",
"       28,52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=see_link\">",
"       \"Withdrawal syndromes with antihypertensive therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A beta-1 cardioselective agent should be used. It is possible that long-acting beta-1 cardioselective agents are more effective than short-acting agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/43\">",
"       43",
"      </a>",
"      ]. Options include atenolol (50 to 100 mg per day orally) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      (5 to 10 mg per day orally) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/32-34,52\">",
"       32-34,52",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Choice of agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blood pressure and heart rate should be monitored closely, with ranges for both established in advance for each patient. Dosing should not be fixed but titrated based upon these targets prespecified for each patient [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"       29",
"      </a>",
"      ]. Titration to a heart rate between 60 and 65 beats per minute is suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with heart failure or with preexisting bronchospastic lung disease not previously treated with a beta blocker, the possibility of exacerbating these conditions must be weighed against the potential benefit.",
"     </li>",
"     <li>",
"      For patients who receive beta blockers preoperatively and cannot take them orally in the perioperative period, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      can be used [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29,32\">",
"       29,32",
"      </a>",
"      ]. The previous dose of oral beta blocker should be restarted when the patient is able.",
"     </li>",
"     <li>",
"      We suggest starting beta blockers days, if not weeks before surgery.",
"     </li>",
"     <li>",
"      There are no data about the duration of therapy. We suggest that beta blockers be continued for at least one month after surgery; they are usually continued indefinitely since most of these patients have underlying heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with major society guidelines recommendations for continuing beta blockers in the perioperative period in patients already on them for appropriate reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     ACCF/AHA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    focused update (of the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline update on perioperative beta blocker therapy for noncardiac surgery) on perioperative beta blockade made the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A strong recommendation to continue in patients previously on these agents.",
"     </li>",
"     <li>",
"      A weak recommendation in patients undergoing vascular or intermediate-risk surgery who have coronary artery disease (CAD) OR more than one clinical risk factor",
"     </li>",
"     <li>",
"      A very weak recommendation in patients undergoing vascular surgery who have a single clinical risk factor in the absence of CAD or in those who have no clinical risk factors",
"     </li>",
"     <li>",
"      For those patients in whom a beta blocker should is started, the process should begin days to weeks before elective surgery and the dose should be carefully titrated. A heart rate of 60 to 80 beats per minute (in the absence of hypotension) in the perioperative period was thought reasonable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     ESC/ESA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009",
"    <span class=\"nowrap\">",
"     ESC/ESA",
"    </span>",
"    guidelines for pre-operative risk assessment and perioperative cardiac management in non-cardiac surgery made the following recommendations regarding perioperative beta blocker use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers should be given in all patients undergoing high-risk surgery, have ischemic heart disease (recommended), or have myocardial ischemia on pre-operative testing, and considered in patients undergoing intermediate-risk surgery or those undergoing low-risk surgery AND with risk factors. Continuation of beta blocker therapy was also considered useful in patients previously treated",
"     </li>",
"     <li>",
"      Treatment should be initiated between 30 and 7 days before surgery",
"     </li>",
"     <li>",
"      The preferred initial drugs and doses were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      2.5 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate 50 mg daily. Adjustment before surgery should achieve a resting heart rate between 60 to 70",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      with a systolic blood pressure greater than 100 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the results of POISE and the subsequent 2008 meta-analysis, we believe that the totality of evidence argues against the initiation of prophylactic perioperative beta blocker therapy in MOST patients undergoing noncardiac surgery. While beta blockers appear to decrease the risk of perioperative MI, the consistent increases in the rate of stroke across all trials, and the increase in total mortality in the POISE trial, suggest net harm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We acknowledge that POISE does not exclude benefit in high-risk patients, as the majority of patients in POISE were RCRI 1 or 2. Patients with RCRI &ge;3 may account for as few as 2 percent of all patients. Similarly POISE does not exclude benefit in patients undergoing high-risk vascular surgery nor in those receiving lower doses of perioperative beta blockers.",
"   </p>",
"   <p>",
"    The percent of all patients referred for surgery who could benefit from the use of beta blockers ONLY in the perioperative period is unknown. However, it is likely to be small, given that many patients have indications for long term beta blocker use for reasons other than surgery.",
"   </p>",
"   <p>",
"    We support the initiation and maintenance of beta blockers in perioperative patients who meet criteria for their long term use, such as those with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stable angina (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30679?source=see_link&amp;anchor=H19#H19\">",
"       \"Beta blockers in the management of stable angina pectoris\", section on 'Summary and recommendations'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Stress induced ischemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link&amp;anchor=H9#H9\">",
"       \"Silent myocardial ischemia: Prognosis and therapy\", section on 'Beta blockers'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      MI (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link&amp;anchor=H23#H23\">",
"       \"Beta blockers in the management of acute coronary syndrome\", section on 'Summary and recommendations'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Heart failure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link&amp;anchor=H3#H3\">",
"       \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Indications for therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=see_link\">",
"       \"Perioperative heart failure in noncardiac surgery\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who are chosen for beta blocker therapy, the optimal timing of initiation is unknown. We suggest not starting hours before surgery as was done in POISE. Irrespective of the timing of initiation, vigilant monitoring of heart rate and blood pressure is required in all patients, as hypotension or hypertension, or bradycardia or tachycardia may adversely affect outcome in high-risk patients.",
"   </p>",
"   <p>",
"    Our recommendations for the use of beta blockers who do not meet the above criteria are discussed separately. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OTHER MEDICAL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with coronary disease or a coronary equivalent (diabetes mellitus, symptomatic carotid artery disease, peripheral artery disease, abdominal aortic aneurysm, chronic kidney disease, or multiple risk factors that confer a 10-year risk of CHD greater than 20 percent) should receive therapy with a statin unless it is not tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Identification of patients at risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients undergoing major vascular surgery, we recommend continuing statin therapy in patients already being treated and, in previously untreated patients, we recommend initiating statin therapy as early as possible before elective vascular surgery based upon the evidence cited below [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/18\">",
"     18",
"    </a>",
"    ]. Although few patients underwent urgent or emergent surgery in the relevant studies, we recommend starting statin therapy, if possible, before vascular surgery in such patients.",
"   </p>",
"   <p>",
"    In contrast, among patients undergoing non-cardiovascular surgery, we recommend statin therapy only in those already being treated or with other indications for treatment. There is no convincing evidence of benefit of starting therapy in those patients who otherwise do not meet accepted criteria for initiation of statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These recommendations are based upon the results of two randomized trials and large observational studies, which suggest that statins improve outcomes in the perioperative period in patients undergoing major vascular surgery through mechanisms in addition to cholesterol lowering (eg, plaque stabilization, reduction in inflammation, decreased thrombogenesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. Further support for benefit from statin therapy comes from an observational study in which cessation of statin therapy was associated with significant cardiovascular harm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the DECREASE III trial, 497 patients who were not taking statin therapy and were scheduled to undergo elective noncardiac vascular surgery were randomly assigned to either 80 mg of extended release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    daily or placebo at least 30 days before the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/53\">",
"     53",
"    </a>",
"    ]. Study medication was continued for at least 30 days after surgery and interruption of therapy during the perioperative period occurred in about 25 percent of patients (median of two days). All patients were either previously receiving beta blocker therapy or were started on it at the time of randomization.",
"   </p>",
"   <p>",
"    The primary end point of myocardial ischemia, defined as release of troponin T",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transient electrocardiographic abnormalities within 30 days of surgery, occurred significantly less often in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    group (10.8 versus 19.0 percent; hazard ratio 0.55, 95% CI 0.34-0.88). The secondary end point of the composite of death from cardiovascular causes and myocardial infarction also occurred significantly less often in the fluvastatin group (4.8 versus 10.1 percent; hazard ratio 0.47, 95% CI 0.24-0.94 respectively). There was no evidence of an increase in skeletal muscle or hepatic injury in the fluvastatin group. A similar magnitude of benefit was noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    therapy in a second, smaller randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although questions have been raised regarding the possibility of protocol violations in this study, we believe that most patients with atherosclerotic cardiovascular disease, including those undergoing vascular surgery, should receive long-term statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term goals of statin therapy are based upon established guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Intravenous nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    can reverse intraoperative myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/60\">",
"     60",
"    </a>",
"    ]. However, a small randomized trial questioned the effectiveness of prophylactic nitroglycerin in reducing perioperative ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/61\">",
"     61",
"    </a>",
"    ]. Furthermore, the decrease in preload induced by nitroglycerin may outweigh its benefits.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    must also be considered in conjunction with the type of anesthetics to be used, since some agents can mimic the venodilating and arterial dilating effects of nitroglycerin. Transdermal nitroglycerin should not be given intraoperatively due to uneven absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE AND POSTOPERATIVE MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Intraoperative monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiography is a relatively insensitive method for the intraoperative detection of myocardial ischemia, although multiple-lead monitoring is more sensitive than single-lead monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/25\">",
"     25",
"    </a>",
"    ]. Despite the limitation in sensitivity, patients with ECG evidence of intraoperative ischemia had, in one report, a relative risk for a cardiac event of 2.7 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, intraoperative transesophageal echocardiography (TEE) is highly sensitive in patients undergoing both cardiac and noncardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/64-67\">",
"     64-67",
"    </a>",
"    ]. If used, echocardiographic monitoring should be continuous, beginning as soon as possible after anesthesia induction, a period of high risk for electrocardiographically-detected ischemia. The occurrence of new or worsening regional wall motion abnormalities indicates myocardial ischemia. Persistence of these changes after surgery may signify a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, from a practical standpoint, continuous echocardiographic monitoring throughout surgery is moderately expensive and labor intensive. As a result, it is likely to be feasible only in the highest risk patients.",
"   </p>",
"   <p>",
"    A pulmonary artery catheter (PAC) is often used perioperatively in high-risk patients with little evidence that outcomes are improved. The best performed study to date found no reduction in in-hospital or six-month mortality with use of the PAC perioperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/69\">",
"     69",
"    </a>",
"    ]. The only significant difference was a higher rate of pulmonary embolism in the PAC group. A similar lack of benefit was noted in a meta-analysis and a large observational study published before the randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be no benefit and possible harm from perioperative use of pulmonary artery catheters (PAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. It has been concluded that no subgroups have been defined for which PAC provides more benefit than harm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/18\">",
"     18",
"    </a>",
"    ]. However, PAC monitoring may be reasonable and appropriate in selected patients. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Intraoperative and postoperative monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Postoperative monitoring for myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative ischemia or infarction can be detected by electrocardiography (ECG) monitoring or troponin measurement. The role of postoperative monitoring with either ECG or troponin is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=see_link&amp;anchor=H4#H4\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Diagnosis and screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=see_link&amp;anchor=H7#H7\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106479263\">",
"    <span class=\"h2\">",
"     Choice of anesthetic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial ischemia and infarction are not uncommon complications of noncardiac surgery and the prognosis is worse in these individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=see_link&amp;anchor=H2#H2\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Incidence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=see_link&amp;anchor=H6#H6\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence to suggest that ischemic preconditioning may reduce the extent of cardiac injury and in that manner improve outcomes following myocardial ischemia in patients undergoing coronary artery bypass graft surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical implications of ischemic preconditioning\", section on 'Coronary artery bypass graft surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on some evidence suggesting a protective preconditioning effect of volatile anesthetics, the TEAM trial randomly assigned 385 high cardiovascular risk patients undergoing noncardiac surgery to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    after induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/72\">",
"     72",
"    </a>",
"    ]. Comparing sevoflurane to propofol, there was no significant difference in the primary composite end point of myocardial ischemia detected by continuous electrocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    troponin elevation (41 versus 40 percent). Unfortunately, the magnitude of cTn elevations that might have been an important endpoint was not reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of estimating and reducing the risk of perioperative cardiac events (eg, cardiac death and nonfatal MI), includes the following four components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defining the urgency of surgery, which may supersede risk stratification. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H46#H46\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Urgency of surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial risk assessment.",
"     </li>",
"     <li>",
"      Refinement of initial risk assessment with noninvasive testing in selected patients.",
"     </li>",
"     <li>",
"      Consideration of therapies that may reduce risk in high-risk patients (eg, revascularization, beta blockers, and statins).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Initial risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial risk assessment consists of three steps. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Initial risk assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the patient have a high-risk condition that is considered a major predictor of risk in the 2007",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines (eg, unstable angina or recent MI [within 7 to 30 days], decompensated heart failure, severe heart valve disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/45/29402/abstract/73\">",
"       73",
"      </a>",
"      ]? Such patients require intensive management and often a delay in or cancellation of surgery.",
"     </li>",
"     <li>",
"      What is the surgery-specific risk of the planned operation?",
"     </li>",
"     <li>",
"      What is the patient-specific risk? This can be estimated using the revised cardiac risk index (RCRI) (",
"      <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"       table 2",
"      </a>",
"      ). The indications for noninvasive stress testing in asymptomatic patients are estimated high risk (&ge;3 RCRI criteria) or intermediate risk (1 to 2 RCRI criteria) plus poor or indeterminate functional status, a history consistent with coronary disease, or high-risk surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H21#H21\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Revised cardiac risk index'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H27#H27\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Noninvasive cardiac testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients requiring emergency surgery typically do not undergo stress testing. In addition, the patient's long-term cardiac prognosis independent of surgery should be taken into account when deciding to proceed with surgery or to perform preoperative coronary revascularization.",
"   </p>",
"   <p>",
"    In addition, patients should be assessed at the time of the preoperative evaluation for the need for long term beta blocker use. In these patients, we recommend the initiation of beta blockers days, and preferably weeks before surgery. For those patients who cannot receive them in this time frame, we advise against their initiation hours before surgery. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Summary'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Angiography and revascularization",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac catheterization and angiography should be performed in patients with high-risk features on noninvasive testing (eg, reversible large anterior wall defect, multiple reversible defects, ischemia occurring at a low heart rate, extensive stress-induced wall motion abnormalities, transient ischemic dilatation). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients in whom preoperative coronary angiography is performed, we recommend revascularization only in patients who have high-risk features that fulfill current criteria applicable to all patients with coronary disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In patients without such indications, the CARP trial and DECREASE-V Pilot Study found no improvement in outcomes with revascularization compared to medical therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"       \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2\">",
"       'Revascularization versus medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG) and the approach to noncardiac surgery in patients who have undergone recent PCi are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are recommended for many patients with known coronary artery disease or myocardial ischemia by stress testing, unless there are contraindications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients scheduled for vascular surgery who have stable CAD, documented myocardial ischemia, or high cardiac risk (RCRI &ge;3) (",
"      <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"       table 2",
"      </a>",
"      ), we suggest initiating perioperative beta blockade (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If beta blocker therapy is prescribed, the drug should be started at least 30 days before surgery and the dose should be titrated. In addition the patient should have close pre- and perioperative monitoring of heart rate and blood pressure to assure that the beta blocker is tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is a reduction in the rate of perioperative myocardial infarction, and possibly a reduction in mortality in these patients, there is a concern about in increased rate of stroke. These issues should be discussed with the patient. Physicians and patients may reasonably choose to defer adding beta blocker therapy in such patients if they feel the risks outweigh the benefits. Examples include patients scheduled for lower risk vascular surgery (carotid endarterectomy) or those with a history of cerebrovascular accident for whom perioperative hypotension might be particularly concerning. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Efficacy and safety summary'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest continuing perioperative beta blockade in patients already being treated with beta blockers (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients at high cardiac risk (RCRI &ge;3) scheduled for intermediate-risk surgery, there is insufficient evidence upon which a recommendation can be made. The benefits and risks of the preoperative initiation of beta blockers in this setting should be discussed in detail with the patient. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Efficacy and safety summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those patients in whom beta blockers are continued or started, guidelines for their use are discussed above. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'If beta blockers are used'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients undergoing elective major vascular surgery, we recommend continuing statin therapy in patients already being treated and, in previously untreated patients, initiating statin therapy as soon as possible before elective vascular surgery (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients on statin therapy undergoing urgent or emergent major vascular surgery, we recommend continuing such therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients not on statin therapy undergoing urgent or emergent major vascular surgery, we suggest initiating therapy before surgery, if possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Over the long-term, we recommend that statin therapy be titrated to recommended goals (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that pulmonary artery catheters NOT be routinely used perioperatively (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Intraoperative and postoperative monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for the use of postoperative electrocardiography or troponin measurement to detect myocardial ischemia are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=see_link&amp;anchor=H4#H4\">",
"       \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Diagnosis and screening'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=see_link&amp;anchor=H7#H7\">",
"       \"Perioperative myocardial infarction after noncardiac surgery\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/1\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/2\">",
"      Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/3\">",
"      Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/4\">",
"      Wesorick DH, Eagle KA. The preoperative cardiovascular evaluation of the intermediate-risk patient: new data, changing strategies. Am J Med 2005; 118:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/5\">",
"      Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. American College of Physicians. Ann Intern Med 1997; 127:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/6\">",
"      Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997; 127:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/7\">",
"      Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology (ESC), Poldermans D, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/8\">",
"      Fleisher LA, Eagle KA. Clinical practice. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/9\">",
"      Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med 1995; 333:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/10\">",
"      Monaco M, Stassano P, Di Tommaso L, et al. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study. J Am Coll Cardiol 2009; 54:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/11\">",
"      Bartels C, Bechtel JF, Hossmann V, Horsch S. Cardiac risk stratification for high-risk vascular surgery. Circulation 1997; 95:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/12\">",
"      Froehlich JB, Karavite D, Russman PL, et al. American College of Cardiology/American Heart Association preoperative assessment guidelines reduce resource utilization before aortic surgery. J Vasc Surg 2002; 36:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/13\">",
"      Almanaseer Y, Mukherjee D, Kline-Rogers EM, et al. Implementation of the ACC/AHA guidelines for preoperative cardiac risk assessment in a general medicine preoperative clinic: improving efficiency and preserving outcomes. Cardiology 2005; 103:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/14\">",
"      McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/15\">",
"      Garcia S, Moritz TE, Goldman S, et al. Perioperative complications after vascular surgery are predicted by the revised cardiac risk index but are not reduced in high-risk subsets with preoperative revascularization. Circ Cardiovasc Qual Outcomes 2009; 2:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/16\">",
"      Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol 2007; 49:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/17\">",
"      Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). Am J Cardiol 2009; 103:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/18\">",
"      Auerbach A, Goldman L. Assessing and reducing the cardiac risk of noncardiac surgery. Circulation 2006; 113:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/19\">",
"      Domanski M, Ellis S, Eagle K. Does preoperative coronary revascularization before noncardiac surgery reduce the risk of coronary events in patients with known coronary artery disease? Am J Cardiol 1995; 75:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/20\">",
"      Rihal CS, Eagle KA, Mickel MC, et al. Surgical therapy for coronary artery disease among patients with combined coronary artery and peripheral vascular disease. Circulation 1995; 91:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/21\">",
"      Eagle KA, Rihal CS, Mickel MC, et al. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation 1997; 96:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/22\">",
"      Hertzer NR, Young JR, Beven EG, et al. Late results of coronary bypass in patients with peripheral vascular disease. I. Five-year survival according to age and clinical cardiac status. Cleve Clin Q 1986; 53:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/23\">",
"      Hertzer NR, Young JR, Beven EG, et al. Late results of coronary bypass in patients with peripheral vascular disease. II. Five-year survival according to sex, hypertension, and diabetes. Cleve Clin J Med 1987; 54:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/24\">",
"      Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998; 88:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/25\">",
"      Stone JG, Fo&euml;x P, Sear JW, et al. Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. Anesthesiology 1988; 68:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/26\">",
"      Raby KE, Brull SJ, Timimi F, et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg 1999; 88:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/27\">",
"      Bodenheimer MM. Noncardiac surgery in the cardiac patient: what is the question? Ann Intern Med 1996; 124:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/28\">",
"      Poldermans D, Boersma E. Beta-blocker therapy in noncardiac surgery. N Engl J Med 2005; 353:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/29\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/30\">",
"      Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 331:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/31\">",
"      Fleisher LA, Poldermans D. Perioperative beta blockade: where do we go from here? Lancet 2008; 371:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/32\">",
"      Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/33\">",
"      Eagle KA, Froehlich JB. Reducing cardiovascular risk in patients undergoing noncardiac surgery. N Engl J Med 1996; 335:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/34\">",
"      Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/35\">",
"      Poldermans D, Boersma E, Bax JJ, et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001; 22:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/36\">",
"      Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005; 294:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/37\">",
"      Dunkelgrun M, Boersma E, Schouten O, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009; 249:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/38\">",
"      Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/39\">",
"      Yang H, Raymer K, Butler R, et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006; 152:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/40\">",
"      Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/41\">",
"      Bangalore S, Wetterslev J, Pranesh S, et al. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008; 372:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/42\">",
"      Auerbach AD, Goldman L. beta-Blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 2002; 287:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/43\">",
"      Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ 2005; 331:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/44\">",
"      Wallace AW, Au S, Cason BA. Perioperative &beta;-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology 2011; 114:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/45\">",
"      Poldermans D, Hoeks SE, Feringa HH. Pre-operative risk assessment and risk reduction before surgery. J Am Coll Cardiol 2008; 51:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/46\">",
"      Feringa HH, Bax JJ, Boersma E, et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. Circulation 2006; 114:I344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/47\">",
"      Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006; 48:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/48\">",
"      Flu WJ, van Kuijk JP, Chonchol M, et al. Timing of pre-operative Beta-blocker treatment in vascular surgery patients: influence on post-operative outcome. J Am Coll Cardiol 2010; 56:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/49\">",
"      Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001; 141:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/50\">",
"      Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; :CD003566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/51\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/52\">",
"      American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, et al. 2009 ACCF/AHA focused update on perioperative beta blockade. J Am Coll Cardiol 2009; 54:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/53\">",
"      Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009; 361:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/54\">",
"      Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/55\">",
"      Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/56\">",
"      Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/57\">",
"      O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/58\">",
"      Schouten O, Hoeks SE, Welten GM, et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007; 100:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/59\">",
"      Rodseth R, Devereaux PJ. ACP Journal Club. Review: Perioperative statins reduce perioperative MI and AF in statin-na&iuml;ve patients. Ann Intern Med 2012; 156:JC6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/60\">",
"      Coriat P, Daloz M, Bousseau D, et al. Prevention of intraoperative myocardial ischemia during noncardiac surgery with intravenous nitroglycerin. Anesthesiology 1984; 61:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/61\">",
"      Dodds TM, Stone JG, Coromilas J, et al. Prophylactic nitroglycerin infusion during noncardiac surgery does not reduce perioperative ischemia. Anesth Analg 1993; 76:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/62\">",
"      Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002; 39:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/63\">",
"      Raby KE, Barry J, Creager MA, et al. Detection and significance of intraoperative and postoperative myocardial ischemia in peripheral vascular surgery. JAMA 1992; 268:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/64\">",
"      Smith JS, Cahalan MK, Benefiel DJ, et al. Intraoperative detection of myocardial ischemia in high-risk patients: electrocardiography versus two-dimensional transesophageal echocardiography. Circulation 1985; 72:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/65\">",
"      Clements FM, de Bruijn NP. Perioperative evaluation of regional wall motion by transesophageal two-dimensional echocardiography. Anesth Analg 1987; 66:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/66\">",
"      Kato M, Nakashima Y, Levine J, et al. Does transesophageal echocardiography improve postoperative outcome in patients undergoing coronary artery bypass surgery? J Cardiothorac Vasc Anesth 1993; 7:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/67\">",
"      Gewertz BL, Kremser PC, Zarins CK, et al. Transesophageal echocardiographic monitoring of myocardial ischemia during vascular surgery. J Vasc Surg 1987; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/68\">",
"      H&auml;ggmark S, Hohner P, Ostman M, et al. Comparison of hemodynamic, electrocardiographic, mechanical, and metabolic indicators of intraoperative myocardial ischemia in vascular surgical patients with coronary artery disease. Anesthesiology 1989; 70:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/69\">",
"      Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/70\">",
"      Barone JE, Tucker JB, Rassias D, Corvo PR. Routine perioperative pulmonary artery catheterization has no effect on rate of complications in vascular surgery: a meta-analysis. Am Surg 2001; 67:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/71\">",
"      Polanczyk CA, Rohde LE, Goldman L, et al. Right heart catheterization and cardiac complications in patients undergoing noncardiac surgery: an observational study. JAMA 2001; 286:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/72\">",
"      Lurati Buse GA, Schumacher P, Seeberger E, et al. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation 2012; 126:2696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/45/29402/abstract/73\">",
"      Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:e418.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6615 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29402=[""].join("\n");
var outline_f28_45_29402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INITIAL RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REVASCULARIZATION VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CARP trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DECREASE-V pilot study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Systematic versus selective screening angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H948409998\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preoperative PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Patients who cannot undergo revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ROLE OF BETA BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POISE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Efficacy and safety summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      If beta blockers are used",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Dose and resting heart rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Suggestions for use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - ACCF/AHA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - ESC/ESA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OTHER MEDICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Intravenous nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      INTRAOPERATIVE AND POSTOPERATIVE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Intraoperative monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Postoperative monitoring for myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106479263\">",
"      Choice of anesthetic agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Initial risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Angiography and revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/6615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/6615|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?6/11/6320\" title=\"algorithm 1A\">",
"      ACP algorithm management low or intermediate risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/29/25055\" title=\"algorithm 1B\">",
"      ACP algorithm management high risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/4/33860\" title=\"algorithm 2\">",
"      Cardiac risk management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/6615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/56/27532\" title=\"table 1\">",
"      ACC AHA prediction periop risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/4/43083\" title=\"table 2\">",
"      Revised cardiac risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/2/7212\" title=\"table 3\">",
"      ACC AHA CV risk noncard surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/47/38652\" title=\"table 4\">",
"      ACC AHA angio periop evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30679?source=related_link\">",
"      Beta blockers in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6344?source=related_link\">",
"      Elective noncardiac surgery after percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40360?source=related_link\">",
"      Medical therapy to prevent complications after coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29975?source=related_link\">",
"      Perioperative myocardial infarction after noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_45_29403="Effect of drugs on calcineurin inhibitor concentrations";
var content_f28_45_29403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effect of drugs on calcineurin inhibitor concentrations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Increase CNIs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Decrease CNIs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diltiazem (potent)",
"       </td>",
"       <td>",
"        Carbamazepine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil (potent)",
"       </td>",
"       <td>",
"        Rifabutin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole (potent)",
"       </td>",
"       <td>",
"        Phenobarbital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        Caspofungin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketoconazole (potent)",
"       </td>",
"       <td>",
"        Phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voriconazole (potent)",
"       </td>",
"       <td>",
"        Rifampin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicardipine",
"       </td>",
"       <td>",
"        St. John's Wort",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clotrimazole",
"       </td>",
"       <td>",
"        Sirolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nifedipine (mild effect)",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Itraconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Troleandomycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anil Chandraker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29403=[""].join("\n");
var outline_f28_45_29403=null;
var title_f28_45_29404="Rx of orthostatic hypotension";
var content_f28_45_29404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of chronic orthostatic hypotension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Correct precipitating factors (eg,",
"hypovolemia) and withdraw offending drugs (diuretics, vasodilators,",
"tranquilizers and sedatives)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Physical measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raise the head of the bed by 10 to 20&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arise slowly, in stages, from supine to seated to standing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dorsiflexion",
"of the feet, handgrip isometric or mental exercise before standing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leg-crossing and squatting may help those",
"with autonomic failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Small meals and coffee only in the early morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jobst stockings and pressure suits (often not acceptable)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fludrocortisone with a high salt diet is the treatment of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sympathomimetic drugs - ephedrine,",
"phenylpropanolamine, pseudoephedrine, phenylephrine, midodrine,",
"methylphenidate, dextroamphetamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Supplementary agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nonsteroidal antiinflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Erythropoietin (if anemic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Third-line and experimental drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vasopressin receptor agonists - dDAVP, lysine vasopressin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Clonidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Yohimbine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Somatostatin analogues - octreotide, especially for",
"postprandial hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dihydroergotamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Beta blockers, especially",
"those with intrinsic sympathomimetic activity such as pindolol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fluoxetine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dihydroxyphenylserine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dopamine antagonists - metoclopramide, domperidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Monoamine oxidase inhibitor with tyramine - can produce severe hypertension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29404=[""].join("\n");
var outline_f28_45_29404=null;
var title_f28_45_29405="COP vs IPF outcome";
var content_f28_45_29405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Comparison of outcome in COP and IPF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Review of nine major published reports in 157 subjects with COP and IPF in whom the diagnosis was confirmed by lung biopsy. The rate of recovery is much higher and that of persistent disease is much lower in the patients with COP. Patients with IPF rarely improved completely with therapy.",
"    <div class=\"footnotes\">",
"     COP: cryptogenic organizing pneumonia, also known as bronchiolitis obliterans organizing pneumonia (BOOP); IPF: idiopathic pulmonary fibrosis.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: King TE Jr, Mortenson RL, Immunol Allergy Clin North Am 1992; 12:461.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_45_29405=[""].join("\n");
var outline_f28_45_29405=null;
var title_f28_45_29406="Contents: Plasma cell disorders";
var content_f28_45_29406=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Plasma cell disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Plasma cell disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Monoclonal gammopathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4041\">",
"           Clinical course and management of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15290\">",
"           Diagnosis of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/58/10154\">",
"           Recognition of monoclonal proteins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple myeloma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/28/36296\">",
"           Allogeneic hematopoietic cell transplantation in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/47/31482\">",
"           Autologous hematopoietic cell transplantation in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/13/35034\">",
"           Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/29/8666\">",
"           Determination of initial therapy in patients with multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/17/16662\">",
"           Diagnosis and management of solitary extramedullary plasmacytoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44535\">",
"           Diagnosis and management of solitary plasmacytoma of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/50/31526\">",
"           Evaluating response to treatment of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/52/32584\">",
"           Initial chemotherapy for patients with high risk multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/1/28698\">",
"           Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/54/18282\">",
"           Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27977\">",
"           Pathobiology of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22551\">",
"           Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/42/16039\">",
"           Plasma cell leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/58/10154\">",
"           Recognition of monoclonal proteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10618\">",
"           Staging and prognostic studies in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/27/30137\">",
"           The use of bisphosphonates in patients with multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30409\">",
"           Treatment of kidney disease in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/15/37114\">",
"           Treatment of relapsed or refractory multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/13/23769\">",
"           Treatment of the complications of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27400\">",
"           Types of renal disease in multiple myeloma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34040\">",
"           Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/14/35049\">",
"           POEMS syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/12/12484\">",
"           Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/11/12470\">",
"           The heavy chain diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/52/36682\">",
"           Treatment of the mixed cryoglobulinemia syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary amyloidosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1530\">",
"           An overview of amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/10/23722\">",
"           Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7418\">",
"           Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/63/12280\">",
"           Gastrointestinal amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/62/35815\">",
"           Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35994\">",
"           Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/29/13784\">",
"           Renal amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23958\">",
"           Treatment of amyloid cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Waldenstrom macroglobulinemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/47/762\">",
"           Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstrm macroglobulinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/47/37626\">",
"           Treatment and prognosis of Waldenstrm macroglobulinemia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8ABA9F7598-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_45_29406=[""].join("\n");
var outline_f28_45_29406=null;
var title_f28_45_29407="Contents: Adolescent medicine";
var content_f28_45_29407=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Adolescent medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Adolescent medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adolescent sexuality",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9866\">",
"           Adolescent sexuality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/5/12378\">",
"           Overview of gender development and clinical presentation of gender nonconformity in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10650\">",
"           Overview of the management of gender nonconformity in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23018\">",
"           Cocaine: Acute intoxication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/47/1784\">",
"           Designer drugs of abuse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33753\">",
"           Inhalant abuse in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/21/22874\">",
"           Opioid intoxication in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/35/570\">",
"           Phencyclidine (PCP) intoxication in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eating disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/2/23593\">",
"           Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44023\">",
"           Eating disorders: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrinology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21865\">",
"           Acquired hypothyroidism in childhood and adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/29/7641\">",
"           Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42201\">",
"           Contraception: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22424\">",
"           Diagnosis and treatment of delayed puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23690\">",
"           Ovarian and fallopian tube torsion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21033\">",
"           Ovarian cysts and neoplasms in infants, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31125\">",
"           Primary dysmenorrhea in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/12\">",
"           Steroid hormone metabolism in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastroenterology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6984\">",
"           Management of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/40/29315\">",
"           Patient information: Chronic abdominal pain in children and adolescents (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/2/10282\">",
"           Body piercing in adolescents and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33770\">",
"           Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/2/10281\">",
"           Confidentiality in adolescent health care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/24/5512\">",
"           Consent in adolescent health care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19000\">",
"           Guidelines for adolescent preventive services",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35993\">",
"           Tattooing in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/49/3864\">",
"           The choking game and other strangulation activities in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/28/39370\">",
"           Treatment of acne vulgaris",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infectious diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1032\">",
"           Clinical features and diagnosis of pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/10/13480\">",
"           Clinical trials of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/56/3976\">",
"           Disseminated gonococcal infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11992\">",
"           Pathogenesis of and risk factors for pelvic inflammatory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/17/19738\">",
"           Recommendations for the use of human papillomavirus vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37689\">",
"           Sexually transmitted diseases: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/39/26229\">",
"           The life cycle, natural history, and immunology of human papillomaviruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35832\">",
"           Treatment of pelvic inflammatory disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutritional issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/24/16778\">",
"           Adolescent eating habits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40040\">",
"           Calcium requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23735\">",
"           Dietary energy requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42967\">",
"           Fast food for children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/4/8266\">",
"           Vegetarian diets for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/3/29753\">",
"           Zinc deficiency and supplementation in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychosocial issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/12/15561\">",
"           Date rape: Identification and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/38/33385\">",
"           Date rape: Risk factors and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/10/5289\">",
"           Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15736\">",
"           Effect of antidepressants on suicide risk in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38071\">",
"           Evaluation and management of suicidal behavior in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/26/13738\">",
"           Overview of treatment for adolescent depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/42/40617\">",
"           Peer violence and violence prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30538\">",
"           Psychopharmacological treatment for adolescent depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4328\">",
"           Psychosocial treatment for adolescent depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23834\">",
"           Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40343\">",
"           Television and media violence",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Reproductive health issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9866\">",
"           Adolescent sexuality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42201\">",
"           Contraception: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/45/34522\">",
"           Depot medroxyprogesterone acetate for contraception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11402\">",
"           Diagnosis and treatment of endometriosis in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17529\">",
"           Management of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21033\">",
"           Ovarian cysts and neoplasms in infants, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/37/3673\">",
"           Overview of breast disorders in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/49/42776\">",
"           Overview of breast masses in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/18/35113\">",
"           Overview of causes of genital tract bleeding in women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39306\">",
"           Overview of contraception",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35973\">",
"           Patient information: Adolescent sexuality (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/31/10744\">",
"           Pregnancy in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31125\">",
"           Primary dysmenorrhea in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/12\">",
"           Steroid hormone metabolism in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urologic issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-50D18E0331-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_45_29407=[""].join("\n");
var outline_f28_45_29407=null;
